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ABSTRACT 
 
Chronic hepatitis B virus (HBV) infection is endemic to sub-Saharan Africa, and despite the 
availability of anti-viral agents, there is currently no cure.  This double stranded DNA virus is 
hepatotropic, and active viral replication results in two genomic equivalents, the relaxed circular 
DNA (rcDNA) and covalently closed circular DNA (cccDNA).  The virion encapsulated rcDNA 
contains a partially synthesised positive DNA stand and a gap region within the negative strand.  
After infection of hepatocytes, the rcDNA is repaired in the nucleus to form cccDNA.  An 
important objective of HBV therapy is the elimination of cccDNA, as its persistence within 
hepatocytes has been attributed to chronic HBV infection.  Therefore a reliable assay for this 
replication intermediate is crucial.  The objective of this study was to develop a method based 
on real-time PCR to detect and quantify HBV cccDNA.  PCR primers which flank the rcDNA gap 
were designed to amplify cccDNA whilst primers flanking the pre-S1 region quantify total HBV 
DNA.  Viral DNA was extracted from HepG2.2.15 cells, along with serum and livers from HBV 
transgenic mice.  According to this assay, cccDNA was readily detectable in transgenic mouse 
livers, but was present at low concentrations in serum samples.  The intrahepatic HBV DNA 
profile of transgenic mice was found to be 40% cccDNA to 60% rcDNA.  In HepG2.2.15 cells, 
only 2% of HBV DNA was cccDNA whilst the majority was in the form of rcDNA.  These results 
were validated using non-radioactive Southern blot hybridisation.  Additionally, it was 
established that although RNAi-based effecters inhibit HBV replication, established cccDNA 
pools were not eliminated.  Real-time PCR provides a convenient platform for HBV cccDNA 
detection as it allows for the rapid simultaneous amplification and quantification of a specific 
DNA target through either non-specific or specific DNA detection chemistries. In conclusion, this 
HBV qPCR assay should enable improved monitoring of patients’ responses to antiviral therapy.  
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CHAPTER  1  –  INTRODUCTION 
 
1.1  Hepatitis B virus biology 
 
1.1.1   Pathogenesis and chronic HBV  
 
Hepatitis B virus (HBV), a member of the Hepadnaviridae family, is an enveloped partially 
double-stranded DNA virus that predominantly infects hepatocytes, resulting in acute or 
chronic infection (Seeger and Mason, 2000).  Acute infections are readily cleared by the 
host’s immune system, in response to antigenic epitopes presented on the viral envelope or 
the surface of infected hepatocytes (Jung and Pape, 2002).   Chronic infections, however, 
increase the risk of developing hepatocellular carcinomas (HCC) and cirrhosis, decades 
after initial infection (Kao and Chen, 2002; Lai et al., 2003; Seeger and Mason, 2000).  It is 
estimated that over 350 million people are chronically infected with HBV, which is 
responsible for between 60 to 80% of all HCC incidences worldwide (reviewed by Lavanchy, 
2004).   Furthermore, the World Health Organisation (WHO) International Agency for 
Research on Cancer (IARC) has declared chronic HBV infection carcinogenic to humans 
(IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. and International 
Agency for Research on Cancer., 1994).  
  
The probability of an acute infection developing into chronic HBV is dependent on both 
cytolytic and non-cytolytic immune responses.  Children and immunocompromised adults 
are more likely to develop chronic infections as their immune systems are immature or 
depleted (Fattovich et al., 2008; Seeger and Mason, 2000).  There are four, well 
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characterised phases of disease progression associated with HBV infection (reviewed by 
Custer et al., 2004; Fattovich et al., 2008; Kao and Chen, 2002; Lai et al., 2003).  These 
include: 1) active viral replication and immune tolerance, 2) immune clearance and 
symptomatic hepatitis, 3) inactive carrier with low level replication, and 4) reactivation or 
occult infection.  The first phase, active viral replication and immune tolerance, is associated 
with high levels of serum HBV DNA, the prevalence of the HBV e antigen (HBeAg), and 
normal serum alanine aminotransferase (ALT) concentrations, correlating with typical liver 
histology and no defining symptoms.  The immune clearance and symptomatic hepatitis 
phase presents as mild to severe hepatitis caused by immune-mediated inflammation and 
fibrosis.  This is a result of immune activation and subsequent HBeAg seroconversion.  The 
third phase is associated with the clearance of serum HBV DNA, normal ALT 
concentrations, and the presence of anti-HBe.  Acute infections are readily cleared after this 
stage, however if seroconversion is not achieved and viral replication persists, the infection 
is regarded as chronic.  The development of chronic HBV requires the administration of anti-
viral therapies to assist in viral clearance.  The final stage, reactivation or occult infection, is 
dependent on the persistence of covalently closed circular DNA (cccDNA), which can 
remain dormant in the nucleus of hepatocytes, thus evading the immune response.  
Reactivation may occur as a consequence of terminating anti-HBV treatment, HBV escape 
mutants, superinfection with hepatitis delta virus (HDV), or conflicting therapies associated 
with immune suppression or co-infections (Feitelson, 1998; Lai et al., 2003).  Although 
chronic HBV can be clinically monitored, there is no existing cure.  Consequently, the most 
efficient means of preventing HBV infection is through immunisation.       
 
A proficient plasma-derived HBV surface antigen (HBsAg) vaccine has been available since 
1981, following which a more universal recombinant DNA vaccine was established 
(Franceschi and Raza, 2008; Kao and Chen, 2002).  As 90-95% of vaccinated individuals 
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are efficiently protected against HBV infection (Margolis, 1998), the WHO has embarked on 
a global campaign to introduce the vaccine into national infant immunisation schemes, 
focussing specifically on endemic countries (Franceschi and Raza, 2008).  Despite the 
availability of a vaccine, HBV still remains endemic to sub-Saharan Africa, with a chronic 
infectivity rate of over 8% accounting for a large incidence of clinically observed cirrhosis 
and HCC (Parkin, 2006). Horizontal transmission of HBV is considered to predominate in 
Africa, where infection prevalence rates of up to 98% have been observed in some rural 
areas of South Africa (Custer et al., 2004).  Furthermore, the risk of developing HCC is 
exacerbated by the exposure of HBV infected individuals to the carcinogenic aflatoxin, as 
well as Human Immunodeficiency Virus (HIV) co-infection (Hainaut and Boyle, 2008).  The 
probability of HIV/HBV co-infection is escalating in sub-Saharan Africa as both diseases 
remain hyper-endemic to the area (Hoffmann and Thio, 2007).  As acquired 
immunodeficiency syndrome (AIDS) can lead to the reactivation of HBV viral replication, 
chronic HBV progresses more rapidly, thus increasing the likelihood of developing HCC 
(Hoffmann and Thio, 2007).   A high incidence of occult HBV infection has also been 
observed in HIV positive patients who have not yet progressed to AIDS (Firnhaber et al., 
2009; Hoffmann and Thio, 2007).  As chronic HBV-related HCC escalates, the mortality rate 
is expected to dramatically increase, further burdening countries with limited medical and 
economic standings (Hainaut and Boyle, 2008).  Accordingly, new sensitive HBV diagnostic 
techniques and advancements in therapeutics are unquestionably required to improve 
chronic HBV patient management.       
 
1.1.2   HBV DNA species and the viral genome 
 
There are two major forms of HBV DNA identified during infection, namely relaxed circular 
DNA (rcDNA) and cccDNA.  rcDNA, which is partially double-stranded, is encapsulated 
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within circulating virions (Robinson et al., 1974; Summers et al., 1975).  This form of HBV 
DNA was primarily isolated from Dane particles, otherwise referred to as circulating viral 
particles or virions, recovered from the serum and liver of chronic HBV patients (Dane et al., 
1970; Huang et al., 1972).  Figure 1.1 illustrates the HBV genome organisation as well as 
the rcDNA conformation.  rcDNA consists of an incompletely synthesised positive DNA 
stand, which is capped at the 5’ end by a short RNA oligomer (Summers and Mason, 1982; 
Will et al., 1987).  A gap region, formed by the association of the 5’ end with the polymerase 
protein, is found in the negative strand (Gerlich and Robinson, 1980).  This gap region is 
flanked by two 11 nucleotide repetitive sequences, Direct Repeat 1 (DR1) and Direct Repeat 
2 (DR2), situated on both the positive and negative strands (Will et al., 1987). These repeats 
act as important recognition sites during viral replication.  The HBV polymerase is inherently 
required during replication, for reverse transcription of the pregenomic RNA (pgRNA), thus 
directing the synthesis of new rcDNA (Hirschman et al., 1971; Kaplan et al., 1973; Robinson 
and Greenman, 1974; Summers and Mason, 1982).  rcDNA acts as the precursor for the 
second HBV DNA construct, the cccDNA.  In the nucleus of hepatocytes, the partially 
synthesised positive DNA strand of the rcDNA is repaired; generating episomal cccDNA 
(Summers and Mason, 1982; Tuttleman et al., 1986).  The cccDNA is the fundamental viral 
transcription intermediate required for replication.   
 
HBV viral replication is dependent on the transcriptional regulation of the cccDNA core 
promoter, which drives the production of viral subgenomic RNAs required for new virion 
assembly.  cccDNA may be epigenetically regulated through the acetylation status of DNA 
coupled histones, and as a result, it is capable of forming minichromosomes (Bock et al., 
2001; Newbold et al., 1995; Pollicino et al., 2006). This allows the virus to remain dormant in 
the nucleus of hepatocytes, often resulting in occult HBV infection (reviewed by Hu, 2002; 
Raimondo et al., 2007).  The HBV genome is approximately 3.2 kilobases (kb) in length, and 
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comprises four overlapping open reading frames (ORFs) which encode the precore/core, 
HBx, and two surface or envelope (pre-S1 and pre-S2/S) genes (reviewed by Moolla et al., 
2002; Nassal, 2008; Robinson, 1977; Seeger and Mason, 2000) as illustrated in Figure 1.1.  
Gene expression is regulated by four individual promoter sequences and two enhancer 
elements.  Transcription from the precore/core ORF yields the 3.5 kb pgRNA which is 
translated to core and polymerase proteins.  Core proteins or HBV core antigens (HBcAg) 
form the viral capsid.  HBV polymerase initiates reverse transcription of the pgRNA to 
produce rcDNA. The precore transcript is also transcribed from the precore/core ORF and is 
translated to produce precore protein which is post-translationally modified and secreted as 
HBeAg.  Like the core gene, the surface or envelope ORF includes two upstream reading 
frames, the pre-S1 and pre-S2 regions.  A 2.4 kb mRNA is transcribed from the pre-S1 ORF 
and yields the large surface protein (L). The pre-S2 ORF is transcribed to produce a 2.1 kb 
mRNA from which the middle (M) and major (S) surface proteins are translated (Heermann 
et al., 1984).  These proteins can be identified immunologically as HBsAg and are essential 
in the formation of new viral envelopes.  The HBx ORF encodes the transactivator protein 
HBx.  The function of HBx is still elusive however it is thought to be important in maintaining 
viral replication in hepatocytes, and facilitate the integration of HBV DNA into the host 
genome (Feitelson, 1998; Kao and Chen, 2002; Robinson, 1977).  Overall, the 
transcriptional regulation of cccDNA drives the transcription of subgenomic viral RNAs and 
pgRNA, which in turn increases the production of new viral proteins leading to increased 
viral replication and HBV viremia.   
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Figure 1.1: Genomic organisation of HBV.  The rcDNA positive strand is only partially synthesised whilst the negative strand 
contains a gap region flanked by DR1 and DR2.  The viral genome comprises of a precore/core, pre-S1, pre-S2/S and HBx ORFs.     
Transcription of the genome yields pgRNA and various subgenomic mRNAs which are transcribed into core, surface and X proteins.    
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1.1.3   Viral infection and replication 
 
Circulating HBV virions denote the infectious particles associated with HBV transmission.  Each 
virion contains an rcDNA genome, which is encapsidated within an icosahedral core or 
nucleocapsid, and subsequently enclosed inside a lipid envelope.  The capsid comprises 
dimerised HBV core proteins and the envelope incorporates the L, M and S surface proteins 
(Blum et al., 1989; Nassal, 2008).  HBV is primarily hepatotropic, however the virus has been 
isolated from peripheral blood mononuclear cells (Neurath et al., 1992; Trippler et al., 1999).  
Figure 1.2 outlines hepatocyte infection and the viral replication strategy of HBV, which has 
been studied extensively over the past three decades (Blum et al., 1989; Nassal, 2008; Seeger 
and Mason, 2000; Summers and Mason, 1982; Will et al., 1987).    
 
Initially the viral envelope attaches to the cellular membrane of hepatocytes and the capsid is 
internalised most likely through clathrin-mediated endocytosis (Cooper and Shaul, 2006).  The 
pre-S1 and pre-S2 regions of the surface proteins have been shown to be central in viral 
attachment and entry; however this process is still not fully understood (Glebe and Urban, 2007; 
Neurath et al., 1986; Neurath et al., 1992).  Once the capsid has been released into the 
cytoplasm of the hepatocyte, it locates to the nuclear pore complex on the membrane surface of 
the nucleus.   The core dissociates releasing the rcDNA into the nucleus where it is repaired, 
resulting in cccDNA.   The establishment of this proviral DNA entails the removal of the 
polymerase and RNA oligomer from the 5’ ends of the negative and positive strands 
respectively, followed by positive strand synthesis and the ligation of the 3’ and 5’ ends flanking 
the gap region (Blum et al., 1989).   Intact episomal cccDNA is the transcriptional intermediate 
required for HBV replication and virion assembly.  
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Figure 1.2: Hepatitis B virus replication cycle.  In the cytoplasm the viral genome is released from the capsid and translocates to 
the nucleus.  rcDNA is then repaired to form cccDNA from which pgRNA as well as various subgenomic mRNAs are transcribed.  
The mRNAs are translated into proteins required for virion assembly whilst the pgRNA associates with polymerase and the new core 
proteins.  Within the capsid, the pgRNA is reverse transcribed to form rcDNA.  Inside the endoplasmic reticulum, surface proteins 
surround the virion allowing the virus to bud out of the cell.     
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The cccDNA is transcribed, with the aid of host transcription factors, yielding various 
subgenomic mRNAs and pgRNA (Blum et al., 1989).  The subgenomic RNAs include the two 
surface mRNAs and the HBx transcript which are exported to the cytoplasm and translated.  
pgRNA is transcribed from the negative strand of cccDNA, resulting in a greater than genome 
length RNA template required for rcDNA synthesis (as previously described).  The pgRNA is 
also exported to the cytoplasm, where it is translated into core particles and the viral 
polymerase.  Association of the pgRNA with a viral polymerase and core protein dimers drives 
nucleocapsid formation (Summers and Mason, 1982).  Each core protein is divided into two 
domains, the core domain and the protamine domain.  The core domain facilitates capsid 
assembly whilst the protamine domain binds the pgRNA/polymerase complex (Hatton et al., 
1992).  The polymerase protein, like core, is also organised into two domains.  The first, a 
terminal protein domain, facilitates pgRNA packaging and DNA priming whilst the second, a 
carboxy-terminal domain, has reverse transcriptase and RNaseH activity (reviewed by Seeger 
and Mason, 2000).  Once the pgRNA and polymerase have been successfully encapsidated the 
RNA genome undergoes reverse transcription.   
 
The complex strategy of HBV reverse transcription has been extensively reviewed (Beck and 
Nassal, 2007; Nassal, 2008; Seeger and Mason, 2000; Will et al., 1987) and will only be briefly 
described.  During core protein encapsulation, the polymerase associates with an epsilon (ε) 
structure, created by a stem-loop present on the 5’ end of the pgRNA.  This initiates the 
transcription of a 3 to 4 base DNA oligonucleotide that binds to proximal DR1 located at the 
pgRNAs 3’ end.  This initiates reverse transcription of the negative DNA strand.  During this 
transcription, the pgRNA is degraded by the polymerase’s inherent RNaseH activity.  A residual 
5’ capped oligonucleotide, not degraded after negative strand production, primes the initial 
stage of positive DNA synthesis.  This oligonucleotide contains a DR1 coding region that 
corresponds to the DR2 sequence present at the 3’ end of the newly synthesised negative 
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strand.  Only a small portion of the positive strand is assembled as transcription is halted when 
the 5’ terminal end of the negative DNA strand is reached.  To complete the transcription of this 
strand, the small positive oligonucleotide undergoes a template switch, based on the presence 
of a terminal redundancy at the negative strand’s 5’ and 3’ ends.  The positive strand is able to 
switch to the 3’ end of the negative strand and resume elongation.   This results in the 
establishment of the rcDNA genome.  The viral nucleocapsid containing the newly synthesised 
rcDNA either infects the same hepatocyte, expanding the nuclear cccDNA pool, or associates 
with surface proteins and buds out of the cell as a complete virion.   These new virions go on to 
infect other hepatocytes and increase serum viraemia.             
 
1.1.4   Current therapeutics  
 
There is a limited number of registered anti-HBV therapeutic agents designed to treat chronic 
HBV infections, but several potential agents are currently undergoing clinical evaluation 
(Hilleman, 2003).  HBV therapeutics can be broadly divided into two major categories, 
immunomodulators and anti-viral agents (Hilleman, 2003; Lai et al., 2003).  Immunomodulators, 
including interferon-α, -β, and pegylated-interferon-α, act against HBV infected cells by aiding 
the adaptive immune response in eliminating infected hepatocytes.  Interferon therapy has been 
successfully used to treat chronic HBV infections (Wong et al., 1993), however its efficacy is 
based on certain predictors of response such as HBV viraemia, serum ALT levels, host immune 
response, and viral mutations (Hilleman, 2003).  Despite its use for over two decades (Seeger 
and Mason, 2000), the anti-HBV efficacy of interferon is considered to be low and is 
contraindicated by co-infection with HIV (Krastev, 2006).   Anti-viral agents on the other hand 
are more specific inhibitors of HBV as they directly target the virus or elements of its life cycle.  
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Two important classes of anti-viral agents are chemotherapeutics and gene therapies. The 
nucleotide and nucleoside analogues Lamivudine, Adefovir dipivoxil, Entecavir, Telbivudine, and 
Tenofovir are licensed chemotherapeutics that are used to treat HBV infections (European 
Association For The Study Of The Liver, 2009; Krastev, 2006).  They act by inhibiting viral 
reverse transcriptase and polymerase which in turn halts HBV replication.  Lamivudine, the first 
licensed therapy against chronic HBV, has shown significant anti-HBV efficacy, specifically in 
reducing HBV DNA levels, inhibiting new cccDNA establishment, and reversing liver damage 
(Dienstag et al., 2003; Lai et al., 1998; Yuen et al., 2005).  However long term Lamivudine 
monotherapy results in escape mutants, particularly the YMDD motif mutation found within the 
viral polymerase, leading to reactivation of HBV (reviewed by Fischer et al., 2001).  Adefovir 
dipivoxil and Entecavir have both shown increased efficacy against HBV in comparison to 
Lamivudine (Hilleman, 2003; Krastev, 2006).  Additionally these agents inhibit HBV mutant 
strains, established during prolonged Lamivudine therapy (Lee et al., 2009; Ono-Nita et al., 
1999).  Telbivudine and Tenofovir have recently become available for chronic HBV treatment 
(Delaney et al., 2006; Osborn, 2009), and they also exhibit activity against HIV (Fung et al., 
2002; Low et al., 2009) which may be useful for treating HBV/HIV co-infections.  Although 
nucleotide and nucleoside analogues have proven efficacy against HBV they are unable to 
eradicate established cccDNA reservoirs.  Furthermore, long term treatment is mandatory as 
cessation of therapy often results in HBV reactivation or viral mutations.  Anti-viral gene 
therapies, including RNA interference (RNAi) effecters, antisense compounds, ribozymes and 
aptamers, have shown promise in the fight against persistent infectious diseases (Schreier, 
1994; Uprichard, 2005), particularly chronic HBV (Arbuthnot et al., 2005; Hilleman, 2003).    
 
RNAi is a naturally occurring RNA-dependant gene silencing mechanism (Agrawal et al., 2003; 
Fire et al., 1998; reviewed by Hammond et al., 2001), which has more recently been developed 
for therapeutic applications (reviewed by Aagaard and Rossi, 2007).  Many RNAi effecters 
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expressing short hairpin RNAs (shRNA), short interfering RNAs (siRNA) and microRNA 
(miRNA) shuttles have been shown to efficiently knock down HBV replication (Arbuthnot et al., 
2005; Arbuthnot and Thompson, 2008; Carmona et al., 2006; Chattopadhyay et al., 2009; Ely et 
al., 2008; Kayhan et al., 2007; Konishi et al., 2003; Li et al., 2007; Liu et al., 2004; Wu et al., 
2007).  This, in turn, successfully impedes reverse transcription and virion assembly.  The 
fundamental challenge associated with gene therapy is the facilitation of exogenous nucleic acid 
transfer into infected cells, primarily through chemical modifications  and delivery vectors 
(reviewed by Chen et al., 2008).  Despite the availability of diverse immunomodulators, 
chemotherapeutics and gene therapies, there is no cure for chronic HBV and total eradication of 
the virus is rarely accomplished.   
 
1.1.5   Persistence of cccDNA 
 
The persistence of episomal cccDNA represents a major hurdle in the treatment of chronic HBV, 
as established infections are refractory to inhibition by approved anti-viral therapies.  This is 
problematic as cccDNA determines the replicative activity of the virus, transcribing all pgRNA 
and viral mRNA from its genome.  As cccDNA is epigenetically regulated (Pollicino et al., 2006) 
it is able to remain dormant in the nucleus of hepatocytes, establishing a latent or occult 
infection (Mulrooney-Cousins and Michalak, 2007; Rehermann et al., 1996).  Consequently, 
monitoring HBV clearance during anti-viral drug regimes remains a challenge.  Although 
markers of infection may indicate eradication of the virus, the persistence of cccDNA often 
results in the re-emergence of infection after cessation of therapy (Levrero et al., 2009).  To 
maintain this stable infection, cccDNA relies on the host for minichromosome formation and viral 
gene transcription.   
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Throughout infection, a single hepatocyte is capable of retaining multiple copies of cccDNA, 
generally ranging between 1 and 50 molecules per cell (Newbold et al., 1995; Wong et al., 
2004; Zhang et al., 2003), but up to 173 replicates have been clinically observed (Chen et al., 
2004).  As each cell preserves its own viral pool, the number of cccDNA replicates fluctuates 
between hepatocytes.  There are three major factors involved in sustaining the cccDNA viral 
pool, the immune-mediated, virological, and epigenetic factors (reviewed by Levrero et al., 
2009).  Immune-mediated factors contribute to the dilution and/or clearance of cccDNA.  This 
includes non-cytolytic cytokines, which block viral replication and new cccDNA formation 
(Guidotti et al., 1999; Thimme et al., 2003) and cytotoxic T lymphocytes, which destroy infected 
hepatocytes (Fisicaro et al., 2009; Thimme et al., 2003).  Constant cellular proliferation 
additionally dilutes the cccDNA pool during consecutive mitotic divisions (Mason et al., 2007; 
Summers et al., 2003).  Despite this, immune-mediated clearance of cccDNA remains inefficient 
during chronic HBV infection.  Virological factors include HBV infection, replication and 
integration.  Viral mutagenesis is the most important virological factor associated with cccDNA 
persistence, as escape mutants facilitate re-infection.  Host immunity and anti-viral therapies 
further exacerbate the rate of mutation as a result of selection pressure (reviewed by Locarnini, 
2005).  Finally, epigenetic factors facilitate organisation of cccDNA into minichromosomes, 
regulating transcription of the viral genome.  Nuclear histone and non-histone proteins associate 
with the cccDNA to create a chromatin-like structure (Bock et al., 2001; Newbold et al., 1995).  
This minichromosome is transcriptionally regulated, based on the acetylation and methylation 
status of key histones (Pollicino et al., 2006).  HBV chromatin remodelling results in the 
recruitment of host transcription factors (Levrero et al., 2009), ultimately permitting viral 
replication.  Despite the available anti-viral therapies and host immunological responses, 
cccDNA is able to persist as a minichromosome indefinitely.  Chronic HBV infections therefore 
require close clinical monitoring, to detect viral escape mutants and HBV reactivation, 
accompanied by personalised anti-viral therapeutic regimes.     
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1.1.6   Detecting HBV infection 
 
Multiple serological and intrahepatic markers of HBV infection are detectable during acute and 
chronic hepatitis.  Furthermore, antigen seroconversion and fluctuating viral DNA levels help 
characterise the phases of chronic infection and disease progression (Custer et al., 2004; 
Fattovich et al., 2008; Kao and Chen, 2002; Lai et al., 2003).  In 1965, Blumberg and colleagues 
described the first HBV serological marker, the Australia antigen (Blumberg et al., 1965), now 
more commonly referred to as the HBsAg.  Following this discovery, several viral antigens and 
antibodies have been isolated including HBcAg, HBeAg, and Anti-HBs, Anti-HBc and Anti-HBe.  
Viral antigens are primarily isolated from circulating viral particles found in the serum of infected 
individuals.  As the viral particles encapsulate rcDNA, both serological and molecular diagnostic 
tools may be used to detect infection with HBV.   
 
Serological diagnostics include solid-phase immunoassays, enzyme linked immunosorbent 
assays (ELISA), branched DNA (bDNA) assays, and electron microscopy, whilst molecular 
diagnostics incorporate radioimmunoassay and DNA hybridisations, polymerase chain reaction 
(PCR), reverse transcription PCR (RT-PCR) and real-time quantitative PCR (qPCR) (reviewed 
by Chernesky and Mahony, 1984; Custer et al., 2004; Evans, 2009; Krastev, 2006; Landry et 
al., 1989; Lok, 2000).  Figure 1.3 briefly outlines the basic principles of the HBV ELISA, bDNA 
assay, Southern blot hybridisation, and qPCR. The most universally exploited HBV 
antigen/antibody serological analysis is the ELISA.  This technique has been used since the 
early 1980’s to detect core, surface and e-antigens (Chernesky and Mahony, 1984; Landry et 
al., 1989), as well as to establish HBV seroconversion in order to track the progression of 
chronic carrier states.  The HBsAg is most frequently measured as it is indicative of chronic 
infection and viral replication.  However this viral antigen is capable of producing subviral 
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particles, coincidently used in the first HBV vaccines (McAleer et al., 1984; McAuliffe et al., 
1980), which are essentially non-infectious, micelle-like viral envelopes.  Consequently the 
HBsAg ELISA may be detecting subviral particles and not infectious virions, which makes it 
difficult to gauge the level of HBV DNA infection.   
 
Distinguishing between the two forms of HBV DNA is critical for identifying occult infections, 
chronic disease progression, and determining the efficacy of anti-HBV therapies.  The rcDNA 
form of the virus, confined within the HBV capsid, is readily found circulating throughout the 
blood and the cytoplasm of hepatocytes.  The cccDNA on the other hand is predominantly 
located within the nucleus of infected hepatocytes. In extreme circumstances cccDNA may be 
isolated from the sera or peripheral blood mononucleocytes, however this is generally only true 
for chronic HBV patients with early stage liver damage (Chen et al., 2004) or transgenic animal 
models.  Radioimmunoassays, bDNA assays, and DNA hybridisations are used to detect viral 
DNA from serum samples and liver biopsies.  HBV bDNA, used mainly to quantify serological 
viral loads, amplifies a chemiluminescence signal, enabling detection of low copy sequences 
(Hendricks et al., 1995; Urdea et al., 1991).  Southern blot hybridisations are frequently used to 
distinguish rcDNA and cccDNA from replicative intermediates and single stranded products by 
observing variations in their relative migration patterns (Brechot et al., 1981; Miller and 
Robinson, 1984).  The precise quantification of viral DNA from Southern blot hybridisation is 
complicated and often imprecise.  Therefore, neither ELISA nor Southern blot is able to 
precisely resolve the level of HBV infection.  Advancements in PCR molecular techniques, 
however, permit the direct detection of both serological and intrahepatic HBV DNA allowing 
accurate quantification of viral DNA.   
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Figure 1.3: A brief overview of the most frequently used HBV detection and quantification 
platforms. A) A primary antibody binds and fixes the HBV surface antigen to the ELISA plate. A 
secondary antibody, conjugated to horseradish peroxidase, then binds the antigen. Signal 
emission and HBsAg quantification is determined spectrophotometrically. B) DNA is immobilised 
on a solid phase by capture probes. A sequence specific probe then binds to serum isolated 
rcDNA.  Subsequently, the pre-amplifier binds to the sequence specific probe and the amplifier, 
which contains multiple alkaline phosphatase binding sites, then attaches to the pre-amplifier. 
Alkaline phosphatase is detected by chemiluminescence. C) HBV DNA is UV cross-linked to a 
nylon membrane. Sequence specific probes are labeled with radioactive isotopes, such as γ32P-
ATP, or non-radioactive immunohistochemical markers, like digoxigenin (DIG). Radioactive 
probes are detected using X-ray film or a phosphoimager. Non-radioactive probes require 
conjugation of specific antibodies as well as alkaline phosphatase for chemiluminescence 
detection. D) HBV sequence specific primers bind to the viral DNA.  Polymerase extends the 
primer sequence, incorporating either non-specific or specific fluorescent probes.  SYBR Green 
binds to double stranded DNA during elongation, where as fluorescent probes bind upstream of 
the primer. Detection and quantification is performed by measuring wavelength specific 
fluorescence emission 
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Conventional PCR and RT-PCR are better candidates for viral DNA and pgRNA quantification, 
as they are less laborious than Southern blotting, have higher specificity, and the DNA can be 
detected without using radioactive probes.  Conventional PCR with HBV primers allows for the 
amplification and subsequent detection of total HBV DNA.   This can be successfully exploited 
to determine serological viral loads, which predominantly consists of rcDNA.  The COBAS HBV 
Amplicor Monitor (Roche Diagnostics) is the most extensively used commercially available HBV 
PCR quantification assay (Kessler et al., 1998a; Kessler et al., 1998b; Lopez et al., 2002; 
Valsamakis, 2007).  This competitive PCR, based on the co-amplification of a known 
concentration of target DNA, has been shown to be more sensitive than ELISA’s and branched 
DNA technologies (Pawlotsky et al., 2000), however it still requires an immunological detection 
platform to quantify HBV viral loads.  The PCR is unable to discriminate between rcDNA and 
cccDNA efficiently, making it difficult to monitor intrahepatic HBV.  Nested PCR has been shown 
to successfully amplify cccDNA alone, however radioimmunoassay are still required for 
quantification (Zhang et al., 2003).  RT-PCR on the other hand, entails the reverse transcription 
of pgRNA into complementary DNA before amplification.  By measuring pgRNA levels, one can 
determine the replicative efficacy of the virus and determine if anti-viral therapies, aimed at 
inhibiting viral transcription and translation, are effective (Chou et al., 2005).  But, as it is an 
RNA based assay, it is unable to amplify HBV DNA and thus cannot quantify rcDNA or cccDNA.  
The subsequent development of qPCR, has, however, revolutionised viral DNA detection.   
 
The scientific advancement of PCR technologies has facilitated the real-time amplification, 
detection and analysis of viral DNA in a single reaction.  qPCR allows the rapid quantification of 
HBV viral loads using fluorescence based chemistries.  As it is a single amplification and 
detection procedure, the likelihood of contamination is minimised when compared to 
conventional PCR, and no immunoassays are necessary.  Real-time PCR has been available 
since the early 1990s (Higuchi et al., 1992) and has been developed to routinely screen for 
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bacterial and fungal diseases, viral infections, and human diseases (reviewed by Evans, 2009; 
Mackay et al., 2002).  Detection and quantification is based on fluorogenic probes, designed to 
bind either non-specifically to double stranded DNA, or specifically to regions of single stranded 
DNA.  Numerous HBV qPCR assays have been developed to quantify serological viral loads 
using SYBR-green (Brechtbuehl et al., 2001), Fluorescence resonance energy transfer (FRET) 
probes (Aliyu et al., 2004), and TaqMan probes (Abe et al., 1999; Allice et al., 2007; Cheng et 
al., 2007).   Furthermore, intrahepatic cccDNA can be isolated and measured by qPCR (He et 
al., 2002; Jun-Bin et al., 2003; Singh et al., 2004; Wong et al., 2004).  The clinical monitoring of 
serological and intrahepatic cccDNA would provide insights into disease progression, HBV 
reactivation, and occult infections. Considering that cccDNA is at the heart of HBV replication, is 
able to form minichromosomes, and is involved in viral integration, it only seems rational to 
measure cccDNA when monitoring a patient’s response to therapy, or when designing new anti-
HBV therapeutic agents.  The advances in HBV qPCR allow for the accurate quantification of 
both serological and intrahepatic viral loads as well as the discrimination between rcDNA and 
cccDNA.    
 
 
1.2  The biochemistry of conventional and real-time PCR 
 
PCR is regarded as the ‘gold standard’ for routine clinical detection and diagnosis of many viral 
pathological agents (Evans, 2009).  The development of PCR is accredited to Kary Mullis who, 
with the help of his colleagues, first used this technique to diagnose sickle-cell anaemia (Mullis 
et al., 1986; Mullis and Faloona, 1987; Saiki et al., 1985).  PCR is based on the exponential 
amplification of an in vitro DNA target through repetitive temperature gradient cycles allowing 
end-point quantification.  The biochemistry and methodology of conventional PCR have been 
extensively described (Arnheim and Erlich, 1992; Evans, 2009; Schutzbank and Stern, 1993; Xu 
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and Larzul, 1991).  The amplification of target DNA is an enzymatic reaction which requires 
oligonucleotide primers, thermostable DNA polymerase with an associated buffer, 
deoxyribonucleoside triphosphates (dNTPs), magnesium ions, and the DNA template.  The 
oligonucleotide primers are specifically designed to flank the DNA target allowing subsequent 
amplification of that single region.  The lengths of the primers confer DNA binding specificity 
which is critical to prevent non-specific DNA amplification.  PCR is performed in an automated 
thermocycler permitting the step-wise amplification of target DNA.  
 
Automated PCR includes the cyclic amplification and synthesis of new DNA strands through 
denaturation, annealing, and elongation steps.  Denaturation is performed at high temperatures, 
between 94 – 96 °C, which facilitates the activatio n of the polymerase and the disassociation of 
double-stranded DNA.  Following denaturation, the temperature is decreased to allow annealing 
or hybridisation of the oligonucleotide primers to the target DNA.  Optimal annealing is 
dependent on the melting temperature (Tm) of the individual primers, which is calculated based 
on primer length, GC content, and complementarity of the primer to the template DNA.  Higher 
annealing temperatures improve specificity but reduce the end-point yield.   Subsequently, the 
polymerase extends from the oligonucleotide primers, amplifying the target DNA sequence.  
This elongation step is preferentially performed at 72°C.  Each newly synthesised DNA strand 
then acts as a template for the next reaction cycle, exponentially amplifying the original DNA.  
As automated PCR is a closed system reaction, only end-point or relative quantification can be 
conducted, which is dependent on the simultaneous amplification of a housekeeping gene.  
Therefore conventional PCR is considered semi-quantitative.  These limitations have 
encouraged the development, adaptation and enhancement of conventional PCR to permit the 
rapid, accurate and sensitive quantification of DNA products during exponential amplification.   
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Real-time PCR (qPCR) enables the absolute quantification of specific DNA products using 
fluorescent reporter systems (Heid et al., 1996; Higuchi et al., 1993).  Like conventional PCR, 
the biochemistry and methodology of qPCR has been comprehensively discussed (reviewed by 
Evans, 2009; Kubista et al., 2006; Mackay et al., 2002; Wilhelm and Pingoud, 2003).  Real-time 
quantification allows the measurement of initial target DNA as it undergoes amplification past 
the threshold or crossing point (CP), as well as its exponential accumulation throughout PCR 
cycling.  Detection of amplification is achieved using either fluorescent DNA-binding compounds 
or specific fluorescent oligonucleotide probes.  Non-specific chemistries include intercalating 
agents such as ethidium bromide and SYBR® green DNA binding dyes, which are incorporated 
into the newly synthesised dsDNA during elongation.  The fluorescence emission signals 
generated by these non-specific chemistries are dependent on the length and number of dsDNA 
templates, and not on sequence specificity.  Fluorophore labelled oligonucleotide probes on the 
other hand, are designed to bind exclusively to target sequences.  There are several fluorescent 
and FRET probes currently used during qPCR analysis.  As these primers and probes are 
designed to bind specifically to target DNA sequences, they only emit a signal when they are 
bound to their complementary sequence and therefore they are far more precise than non-
specific dyes.  As different fluorophores emit at diverse wavelengths, oligonucleotide probes 
and primers harbouring distinct fluorophores can be used to detect and quantify numerous DNA 
sequences through a procedure referred to as multiplexing.  This is particularly appealing for the 
detection and diagnosis of viral infections as multiple pathological agents can be investigated 
during a single qPCR.   
 
The LightCycler™ 2.0 is a real-time PCR thermocycler, manufactured by Roche (Germany), 
which contains a single thermal chamber that is able to accommodate up to thirty two samples 
in a reaction (Wittwer et al., 1997).  It employs a blue-light emitting diode for fluorescence 
excitation and photodiodes for emission detection.  Glass capillaries hold the samples which 
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are placed in a circular carousel for thermal cycling.  The practical design of the thermal 
chamber and the multi-wavelength detection platforms result in exceptionally rapid PCR cycling 
which can be multiplexed to detect numerous DNA templates (Betzl, 2000).  The LightCycler™ 
software is used to construct real-time standard curves, permitting absolute quantification of 
DNA, as well as melting curves, to determine specificity (reviewed by Evans, 2009; Kubista et 
al., 2006).  Standard curves are created by generating a logarithmic (log) serial dilution series, 
containing known amounts of target DNA, which are then amplified during PCR.  These 
standards are included in all qPCR reactions as internal controls to prevent inter-assay 
discrepancies.  Melting curves, determined by the first negative derivative of fluorescence 
versus temperature, establish amplification specificity.  A melting curve assists in identifying 
non-specific products, or single base changes and polymorphisms.  The precise and rapid 
amplification properties of the LightCycler™ 2.0 make it a practical and proficient instrument for 
viral DNA quantification. 
 
 
1.3 Aims 
 
Based on the need for an efficient routine HBV cccDNA and rcDNA quantification assay, this 
thesis examines the significance of designing a real-time quantitative PCR method, specifically 
for acquisition on the LightCycler™ 2.0, and applying it to routine laboratory diagnostics.  As 
there is virtually complete sequence homology between rcDNA and cccDNA, a set of qPCR 
primers will be designed to amplify cccDNA alone.  As rcDNA contains an incomplete positive 
DNA strand and a gap region located between DR1 and DR2 (Figure 1.1), cccDNA primers will 
flank both repeats, allowing comprehensive amplification of cccDNA alone.   A second primer 
set will be created to amplify both rcDNA and cccDNA, based on the pre-S1 ORF which is 
common to both HBV genomes.  This will allow the total viral DNA as well as each HBV DNA 
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species to be accurately quantified.  By subtracting cccDNA quantification from total HBV DNA, 
the number of rcDNA copies can be determined.   
 
Real-time PCR fluorescence reporter systems based on non-specific DNA intercalating 
chemistries, using SYBR® Green I, will be used for detection of amplification.  HBV samples, 
acquired from the HepG2.2.15 cell line and hepatitis B transgenic mice, will be exploited for viral 
DNA quantification.  The HBV qPCR assay will be validated using Southern blot hybridisation to 
determine the ability of each technique to detect and quantify HBV DNA.  The efficiency of 
RNAi-based anti-viral agents will be assessed using the HBV qPCR assay.  Both cccDNA and 
rcDNA will be measured to determine whether RNAi is able to knock down these viral genomes 
and abolish HBV replication.      
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CHAPTER  2  –  MATERIALS  AND  METHODS 
 
2.1  HBV plasmids and cell lines  
 
2.1.1   pCH-9/3091 and pHBV1.3x 
 
Replication-competent HBV plasmids, pCH-9/3091 (Nassal et al., 1990), and pHBV 1.3  , 
alternatively designated  pCR-HBVA1 1.3  (Mufamadi, 2008) were used to design HBV DNA 
primers and act as standard positive controls.  Both plasmids are greater than genome length 
constructs, which are capable of replicating when transfected in vitro or in vivo.  The HBV 
plasmid maps are shown in Appendix 5.1.     
 
2.1.2   Plasmid construction and cloning of pTZ-HBVcccR and pTZ-HBVrcR 
 
The pCH-9/3091 plasmid consists of an HBV DNA coding region that is 1.3 times the length of 
HBV DNA.  It therefore encodes a full HBV genome; with certain sequences, such as the pre-
core region, repeated.  The first pre-core sequence is located immediately downstream of the 
CMV promoter, which drives replication.  The second pre-core region is positioned after the X 
protein coding region.  pHBV 1.3  is similar to pCH-9/3091 in that it, too, is a replication 
competent plasmid which is 1.3 times the length of HBV DNA.  However the repeated sequence 
is the X protein coding region, with a slightly truncated pre-core repeat located directly after the 
second X gene (Appendix 5.1).  The use of pCH-9/3091 or pHBV 1.3  to create a standard 
curve is therefore problematic as two sequences will be amplified during PCR.  To overcome 
this, plasmids containing a single copy of the HBV pre-core and X protein regions (cccR) and 
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pre-S1 region (rcR) were constructed to aid in HBV quantification.  Figure 2.1 outlines the 
process of pTZ-HBVcccR and pTZ-HBVrcR cloning as well as the regions of the HBV genome 
chosen for plasmid construction and qPCR analysis. 
 
Design of primers for amplification of ccc-region (cccR) and rc/ccc-region (rcR) 
Primers were designed, based on the sequence of pCH-9/3091 and pHBV 1.3, to flank the 
cccR and rcR.  The cccR denotes a portion of the HBx region, pre-core and core region whilst 
the rcR consists of the pre-S1 region.  Primer analysis and validation was performed using the 
Net Primer analysis software (PREMIER Biosoft International) and the multiple alignment tool, 
BLAST (NCBI). Oligonucleotide primers were synthesised by Inqaba Biotec (Pretoria, Gauteng, 
South Africa) using standard phosphoramidite chemistry.  A 421 bp region of the cccR was 
amplified from pHBV 1.3 using the following primer set:  cccR-F (3935) – 5’ CTG CCG TAC 
CGT CCG  ACC A 3’ (forward), cccR-R (4348) – 5’ CGA ATT CGG TCA ATG TCC ATG CCC  
CAA A 3’ (reverse).  The same primer set amplified a 416 bp region of pCH-9/3091 between 
nucleotides 2779 and 3196.  A 390 bp region of the pre-S1 gene within pHBV 1.3, was 
amplified using the following forward and reverse primers: rcR-F (1901) – 5’ GAC AAA GGG 
ATT AAA CCT TAT TAT CCT GA 3’ (forward), and rcR-R (2284) – 5’ CGA ATT CCC TCC 
GTG TGG GGG AGT GAA 3’ (reverse).  In pCH-9/3091 the rcR primer set amplifies a 348 bp 
region between base pairs 784 and 1132.  Both the cccR and the rcR reverse primers contain 
a single EcoRI restriction site (GAATTC) at their 5’ ends.   
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Figure 2.1: Overview of HBV plasmid construction and cloning.  Primers were designed to 
amplify the 2779-3196 bp ccc-region (cccR) and 784-1132 bp rc/ccc-region (rcR) of pCH-
9/3091.  The cccR included the pre-core, X protein, and polymerase coding sequences.  The 
rcR contained the Pre-S1 and Pre-S2 regions.  An EcoRI restriction site was incorporated 
during amplification.  Final PCR products were ligated into the multiple cloning site of pTZ57R/T, 
and transformed in chemically competent DH5α Escherichia coli.  
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PCR amplification and gel electrophoresis of cccR and rcR 
The HBV plasmids, pCH-9/3091 and pHBV 1.3 were used as a templates for cccR and rcR 
amplification.  The PCR system for cccR amplification included 120 mM Tris-HCL (pH 8.6), 100 
mM HCL, 0.1% Tween-20, 1mM  DTT, 10% glycerol, 3 mM MgCl2, 0.625 U KAPATaq (Kapa 
Biosystems, Observatory, Cape Town, South Africa), 0.4 mM of each dNTP, 15 pmol cccR-F, 
15 pmol cccR-R, and 254 ng of pHBV 1.3 or pCH-9/3091, to a final volume of 25 µl in a 0.5 
ml PCR grade microcentrifuge tube (Axygen Scientific). The rcR PCR system components 
were the same as those used for the cccR amplification except for the substitution of the cccR 
forward and reverse primers with 15 pmol rcR-F and 15 pmol rcR-R.  The PCRs were 
performed in an Eppendorf Mastercycler gradient thermocycler (Eppendorf, NY, USA) under 
the following conditions: initial denaturation at 95°C for 2 min; 25 cycles of 95°C for 30 s, 58°C 
for  30 s, and 72°C for 30 s; final elongation at 7 2°C for 5 min and cooling at 4°C.  Samples 
were analysed using agarose gel electrophoresis.  PCR products were combined with 5 µl of 
6 loading dye (0.125% bromophenol blue; 30% glycerol; 6 Tris-borate-EDTA (TBE) buffer 
[Appendix 5.2.1.]) and loaded into a 2% agarose gel containing 0.0025% Ethidium Bromide. An 
O’GeneRuler (Fermentas, MD, USA) was used as a molecular weight marker.  The products 
were subjected to electrophoresis in 1 Tris-acetate-EDTA (TAE) buffer containing 40 mM Tris 
acetate and 1 mM EDTA (Appendix 5.2.1).  Band migration patterns were evaluated under UV 
transillumination, using the GelLogic 200 imaging system (Kodak, NY, USA) and the Kodak 1D 
image analysis software (Kodak).   
 
Second round PCR amplification of the HBV plasmid amplicons  
Agarose gel bands containing the DNA regions corresponding to the cccR and rcR were 
visualised on a UV transilluminator (UVP, CA, USA) and excised with a sterile surgical blade.  
The DNA was extracted from the gel and purified using the MinElute® Gel Extraction Kit 
(Qiagen, Hilden, Germany).   The cccR and rcR DNA fragments were eluted in 10 µl of best 
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quality water (Sabax, Adcock Ingram, Gauteng, South Africa).  The agarose gel extracted DNA 
products were amplified after a second round of PCR.  The same PCR components including 
cycling conditions and gel electrophoresis (as described in section 2.1.2.2) were used, with the 
substitution of the HBV plasmid with the cccR DNA or rcR DNA.  The second round PCR 
products were used for cloning into the T/A cloning vector pTZ57R/T (Fermentas, Maryland, 
USA).    
 
Ligation of cccDNA region and rc/cccDNA region into pTZ57R/T 
Two plasmids were generated by inserting the cccR or the rcR DNA into a pTZ57R/T vector 
(Fermentas, MD, USA).  The InsTAclone™ PCR Cloning Kit ligation reaction was set up as 
follows: 0.165 µg of pTZ57R/T, 4 µl of 5 Ligation buffer, 7.5 U of T4 DNA ligase and 0.1 µg of 
either cccR DNA PCR product or rcR DNA PCR product, to a final volume of 20 µl in a 1.5 ml 
microcentrifuge tube.  Ligation reactions were incubated at 18°C for 1 hour and 30 minutes.  
Nine microlitre aliquots were gently mixed with 100 µl of chemically competent DH5α 
Escherichia coli (E. coli) (Appendix 5.2.2).   The reaction mixture was incubated on ice for 25 
minutes, heat shocked at 42°C for 90 seconds and fi nally rescued for 2 minutes on ice. The 
transformed E. coli were plated onto Luria-Bertani (LB) agar plates containing ampicillin (100 
µg/ml), 40 µl (20 mg/ml) X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside in dimethyl-
formamide), and 8 µl (100 mg/ml) IPTG (isopropyl-beta-D-thiogalactopyranoside). LB plates 
were incubated at 37°C overnight, followed by 10 mi nute refrigeration at 4°C to enhance the 
colouring of the pTZ57T/R blue colonies.  Five white colonies from each plate (i.e. five cccR 
ligation colonies and five rcR ligation colonies) were picked and individually incubated in sterile 
capped tubes containing 4 ml of LB media (100 µg/ml ampicillin).  The tubes were incubated in 
a shaking incubator (Labcon, Gauteng, South Africa) at 37°C and 200 rpm overnight.  The 
pTZ57R/T plasmid containing the cccR DNA is hereafter referred to as pTZ-HBVcccR and the 
pTZ57R/T plasmid containing the rcR DNA is referred to as pTZ-HBVrcR. 
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Plasmid DNA extraction and restriction digestion analysis 
Cloned plasmids were extracted from the DH5α E. coli bacterial cultures using the High Pure 
Plasmid Isolation Kit (Roche, Germany) [Appendix 5.2.3].  The purified plasmids were eluted 
into a 1.5 ml microcentrifuge tube (Axygen Scientific) with 100 µl of best quality water.  The 
concentration and purity of the extracted plasmids was determined by measuring their relative 
absorbance’s with the NanoDrop® ND-1000 UV-Vis spectrophotometry (NanoDrop 
Technologies, DE, USA).  To determine if the cloned plasmids contain the cccR or rcR inserts, 
two separate restriction digestions were performed (Appendix 5.2.3).  The first was with EcoRI 
whilst the second was an XbaI/BamHI double digestion. Both restriction digests were incubated 
at 37°C for 1 hour, followed by gel electrophoresis  analysis.  DNA bands were observed under 
UV light in the GelLogic 200 imaging system with the 1D image analysis software.  Plasmid 
extractions were stored at -20°C.   
 
Sequencing 
The pTZ-HBVcccR and pTZ-HBVrcR plasmids were sequenced using the BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA) according to the manufacturer’s 
instructions.  Briefly, 100 ng template DNA (pTZ-HBVcccR or pTZ-HBVrcR plasmid) was mixed 
with 1   BigDye sequencing buffer (80 mM Tris-HCL (pH 9.0), 2 mM MgCl2) (Applied 
Biosystems), 1 Ready Reaction Premix (Applied Biosystems), and 3.2 pmol M13 forward 
primer, in a final volume of 10 µl.  Template DNA was amplified by conventional PCR in an 
Eppendorf Mastercycler gradient thermocycler (Eppendorf, NY, USA) under the following 
conditions: initial denaturation at 96°C for 5 minu tes followed by 50 cycles of 96°C for 30 sec, 
50°C for 10 sec and 60°C for 4 min.  Following fina l elongation samples were cooled to 4°C.   
PCR extension products were purified by ethanol precipitation and sequenced by automated 
cycle sequencing.  The sequence of pTZ-HBVcccR is shown in Appendix 5.1.3. 
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2.1.3   HepG2.2.15 cell culture 
 
HepG2.2.15 cells, the human hepatoma cell line HepG2, containing a stably integrated HBV 
genome (Sells et al., 1987), was used to quantify total HBV DNA and cccDNA generated using 
a cell culture model system.  Cells were cultured in 75 cm3 flasks using Dulbecco's Modified 
Eagle Medium (DMEM) (Gibco, Invitrogen, USA) supplemented with 10% fetal calf serum 
(FCS), penicillin (100 000 U/ml), and streptomycin (100 000 µg/ml).  Cells were maintained in a 
humidified incubator at 37°C and 5% CO 2 until confluent.  The cell culture supernatant was 
removed and stored at -20°C.  Adherent cells were g ently washed with 20 ml 1% Phosphate 
Buffered Saline (PBS).  Cells were harvested and stored in 1000 µl of 1% PBS at -20°C.  
 
 
2.2  HBV DNA extraction 
 
2.2.1   HBV transgenic mice  
 
Total DNA from the liver 
A male HBV transgenic mouse (Marion, 2003) was sacrificed and the whole liver harvested.  
Viral DNA was extracted from 50 mg of homogenised liver tissue, using the QIAamp® DNA 
Blood Mini Kit (Qiagen, Hilden, Germany) tissue spin protocol (Appendix 5.2.4), following the 
manufacturer’s instructions. Ethanol precipitation and column binding was performed using 230 
µl 100% ethanol to improve viral DNA extraction.  The viral DNA was eluted in 200 µl of best 
quality water.  The concentration of the elution was determined spectrophotometrically using the 
NanoDrop® ND-1000 with the NanoDrop ND-1000 3.3 software.  Samples were stored at -70°C. 
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Total DNA from the serum 
The blood was set aside to clot for 1 hour at 4°C i n 1.5 ml microcentrifuge tubes.  Samples were 
then centrifuged for 6 minutes at 3000 rpm in an Eppendorf MiniSpin microcentrifuge, rotor F45-
12-11, GE 010 (Brinkmann [Eppendorf], New Haven, CT, USA).  The serum was aspirated and 
transferred to a clean 1.5 ml microcentrifuge tube, followed by centrifugation for an additional 6 
minutes at 3000 rpm in the Eppendorf MiniSpin (Brinkmann) to remove residual blood cells.  
The QIAamp® DNA mini kit blood spin protocol was used to extract viral DNA from 20 µl of 
serum, however carrier DNA was excluded from the extraction.  The HBV DNA was eluted into 
a 1.5 ml microcentrifuge with 100 µl of best quality water and analysed spectrophotometrically 
(Appendix 5.2.5). Serum HBV DNA extractions were stored at -20°C.   
 
DNA extraction from whole virions in serum 
HBV transgenic mouse serum was prepared, as explained in the previous extraction step, and 
treated with two different DNases to destroy all unprotected DNA (genomic DNA and naked 
cccDNA) leaving only whole HBV virions.  Twenty four microlitres of HBV transgenic mouse 
serum was incubated with either 4 µl of gDNA wipe out buffer (Qiagen, Hilden, Germany) for 6 
minutes at 42°C, or with 10 U DNase (Promega, WI, U SA), 3 µl 10 buffer (Promega) and 1.5 
µl best quality water for 30 minutes at 37°C.  The HBV rcDNA, within the whole virions, was 
extracted using the QIAamp® DNA mini kit blood spin protocol (without carrier DNA) and eluted 
in 60 µl best quality water.  Whole virion extractions were analysed using qPCR. 
 
2.2.2   HepG2.2.15 cell line 
 
Total HBV DNA was extracted from 200 µl of cell culture supernatant using the QIAamp® DNA 
Mini Kit blood spin protocol, and 200 µl of HepG2.2.15 cells using the QIAamp® DNA Mini Kit 
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tissue spin protocol.  Extractions were according to the manufacturer’s instructions with one 
adjustment: ethanol precipitation and column binding was performed using 230 µl 100% 
ethanol, instead of 200 ul, as recommended in the protocol. This was found to improve viral 
DNA extraction.  DNA was eluted into a 1.5 ml microcentrifuge tube with 200 µl of best quality 
water. DNA samples were analysed (Appendix 5.2.5) and extractions were stored at -20°C.  
 
 
2.3  Mouse genomic DNA extraction and detection 
 
2.3.1   Extraction of DNA from mouse liver 
 
Mouse genomic DNA was extracted from a normal mouse liver using the tissue protocol from 
the QIAamp® DNA mini kit.  Mouse genomic DNA was eluted in 200 µl of best quality water and 
analysed (Appendix 5.2.5) before storing at -20°C.  
 
2.3.2   Primer design for amplification of St6gal1 mouse liver housekeeping gene 
 
The beta galactoside alpha 2,6 sialyltransferase 1 (St6gal1) gene was selected as a mouse liver 
housekeeping gene (Mouse Genome informatics accession number: 108470, NCBI accession 
number: NM145933) as it is located in the liver as a single copy gene.  The forward and reverse 
St6gal1 primer set was:  St6gal1-F – 5’ GCT TCC CAG AAG ATC CGT TCT CAA GGG G 3’ 
(forward) and St6gal1-R – 5’ AGG GCT GCC TCT CAG CGC ACC CCT G 3’ (reverse). These 
primers amplify a 303 base pair fragment on chromosome 16 of the mouse genome (NCBI 
accession number NT 039624).  Primers were analysed using the Net Primer online software 
(PREMIER Biosoft International) and the BLAST multiple alignment tool (NCBI).  
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Oligonucleotide primers were synthesised by standard phosphoramidite chemistry (Inqaba 
Biotec).   Primers were stored at -20°C.   
 
 
2.4  HBV detection and quantification by Southern blot hybridisation 
 
2.4.1   Design and synthesis of digoxigenin (DIG)-labelled HBV probe 
 
An HBV DNA probe was synthesised using the PCR DIG Probe Synthesis Kit (Roche 
Diagnostics, Germany).  The probe was designed to span a 256 bp region of the pre-S1 gene 
within the HBV, using the following primer set: HBV DNA-F – 5’ TTA TTA TCC AGA ACA TGT 
AGT TAA TCA TTA CTT CC 3’ (forward) and HBV DNA-R – 5’ TTG ATG GGA TTG AAG TCC 
CAA TCT GGA TT 3’ (reverse).  The DIG labelled probe reaction mix included 5 µl of 10 PCR 
buffer, 5 µl of PCR DIG probe synthesis mix, 15 pmol of forward and reverse primer, 2.625 U of 
Enzyme mix, and 58 ng of pCH-9/3091 to a final volume of 50 µl with best quality water.   An 
unlabelled control was included to indicate whether the PCR was successful.  This control 
incorporated all of the components of the DIG labelled probe, except the PCR Dig probe 
synthesis mix was substituted with 5 µl of dNTP stock solution (200 µM of each dNTP).  The 
thermocycling parameters were a 95°C hot start for 2 minutes followed by 30 cycles of 95°C, 
60°C and 72°C (each for 30 seconds).  Final elongat ion was performed at 72°C for 7 minutes 
and cooling at 4°C.  The efficacy of the DIG labell ing reaction was determined by gel 
electrophoresis.  A 5 µl aliquot of the DIG labelled and DIG unlabelled PCR products were 
subjected to electrophoresis on a 1.5% agarose gel (0.0025% Ethidium Bromide) in 1 TAE 
(Appendix 5.2.1) for 30 minutes at 100 V.   A 10 µl aliquot of O’GeneRuler DNA mix was run 
simultaneously to determine whether DIG was successfully incorporated into the labelled probe, 
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indicated by a shift in molecular weight.  Band migration was observed under UV light in the 
GelLogic 200 imaging system with the 1D image analysis software.  DIG labelled probe was 
stored at - 20°C.   
 
2.4.2   Southern blot hybridisation 
 
Concentrated HBV DNA extractions and pCH-9/3091 standards were subjected to 
endonuclease digestion (see section 2.4.4) prior to gel electrophoresis and alkaline capillary 
transfer.  A known dilution series of pCH-9/3091, ranging from 116 ng to 0.11325 ng, was 
included as a positive control, and later used as a standard reference for quantification.  Mouse 
genomic DNA was included as a negative control.  Twenty-five microlitre aliquots were mixed 
with 6 loading dye (Appendix 5.2.1) prior to gel loading.  Electrophoresis was performed using 
a 1% agarose gel (0.00025% Ethidium Bromide) in 1 TAE (Appendix 5.2.1).  O’GeneRuler 
DNA ladder mix was used as a DNA molecular weight marker.  DNA migration was visualised 
under UV light using the GelLogic 200 imaging system.  Additionally, the migratory distance of 
the DNA ladder (in millimetres) from the well, was measured.   
  
Once HBV DNA samples had migrated sufficiently, the gel was trimmed of excess lanes and 
subjected to alkaline transfer using capillary action (Brechot et al., 1981; Southern, 1975).  
Before transfer, the DNA in the gel was denatured and neutralised.  Two 15 minute washes in 
100 ml of 0.5 N NaOH; 1.5 M NaCl solution were used to denature the DNA, whilst 
neutralisation was performed using a single 30 minute wash in 100 ml of neutralising solution (1 
M Tris, 3 M NaCl, pH 7.0).  Alkaline capillary transfer was performed using 20 SSC (Sodium 
chloride sodium citrate buffer)(Appendix 5.2.1).  The DNA was transferred overnight by capillary 
action onto a positively charged Hybond-N+ nylon membrane (GE Healthcare, NJ, USA).  After 
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transfer the membrane was UV crosslinked for 2 minutes at 2000 J and baked at 80°C for 1 
hour.   After baking, the membrane was stored at room temperature until probe hybridization.  
 
Probe hybridisation and detection was adapted from the Roche molecular Biochemicals, DIG 
Application Manual for filter Hybridization (Roche Diagnostics, Germany).  Briefly, 25 ml of DIG 
Easy Hyb buffer (Roche) was heated to 42°C.  A 20 m l aliquot was added to a hybridisation 
cylinder containing the nylon membrane, and incubated for 30 minutes at 42°C in a rotating 
oven.  During the pre-hybridisation step, a 5 µl aliquot of DIG-labelled HBV probe was 
denatured at 95°C for 5 minutes, and mixed with 500  µl of pre-heated DIG Easy Hyb.   The 
remaining 4.5 ml of the pre-hybridisation buffer was later added to the probe.  The DIG Easy 
Hyb buffer was removed from the membrane and the 5.5 ml aliquot of probe and DIG Easy Hyb 
mix, was added.  The Southern blot was allowed to hybridise overnight, at 42°C.   Excess probe 
was removed by washing the membrane as follows: a 20 minute low stringency wash (1% SDS, 
5 SSC) performed at room temperature, followed by two 15 minute high stringency washes 
(1% SDS, 1 SSC) at 42°C.  The Southern blot membrane was remo ved from the hybridisation 
cylinder and rinsed with 200 ml of 1 washing buffer (0.1 M Malic acid, 0.15 M Sodium chloride, 
pH 7.5, 0.03% Tween) for 2 minutes.  The membrane was blocked for 30 minutes in 200 ml of 5 
% blocking buffer (5 g low-fat milk powder in 100 ml 1% PBS) followed by antibody binding (1 µl 
of Anti-Digoxigenin-alkaline phosphatase Fab fragment (Roche Diagnostics, Germany) in 40 ml 
of 1% blocking buffer) for 30 minutes.  Unbound antibody was washed off using four washes of 
200 ml 1 washing buffer, each for 15 minutes, at room temperature.  Finally, to prepare for 
chemiluminescence detection, the membrane was washed with 40 ml of detection buffer (0.1 M 
Tris.HCl, 0.1 M sodium chloride, pH 9.5) for 5 minutes.   
 
Chemiluminescence detection was performed by spreading the substrate for alkaline 
phosphatase, CPD-Star (Roche Diagnostics, Germany), evenly across the membrane.  A 
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transparency film was placed on top of the membrane to aid in the removal of air bubbles and 
excess CPD-Star.  The Southern blot was placed in a developing cassette and under red light, 
Fuji RX film (Fuji, Japan) was inserted on top of the membrane.  The film was exposed for 
between 5 to 20 minutes following which it was developed and fixed.  Analysis was performed 
using image analysis software.    
 
2.4.3   HBV DNA quantification using image analysis software 
 
The Southern blot film was captured as a JPEG image using the GelLogic 200 imaging system 
with the 1D image analysis software.  This image file was imported into the Java-based image 
processing software, ImageJ version 1.41 (Abramoff, 2004) and Southern blot hybridisation 
bands were quantified, using the pCH-9/3091 dilution series as internal standards.  The bands 
were quantified by subtracting the background noise, inverting the image and determining the 
integrated density of each band (using the ImageJ software). 
 
2.4.4   Enzymatic digestions to improve HBV migration patterns 
 
HindIII and EcoRI digestions 
To ensure that the migration of HBV DNA was not hindered by genomic DNA during Southern 
blot hybridisation, HBV DNA extractions and pCH-9/3091 samples were subjected to HindIII 
restriction digestion.  As both murine and human genomic DNA contains multiple HindIII 
restriction sites within their genomes, the DNA will be digested.  This restriction site is absent 
from the HBV genome, therefore HindIII will not affect the HBV DNA.  Before digestion, the 
concentration of total DNA was determined by NanoDrop® ND-1000 UV-Vis spectrophotometry, 
following which the digestion mix was prepared as follows: 1U of HindIII (Fermentas, MD, USA) 
per microgram of DNA and 1 Buffer R (Fermentas, MD, USA).  Samples were incubated at 
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37°C for 1 hour and 15 minutes.  The MinElute® Gel Extraction Kit was used to remove the 
enzyme, degraded DNA, and residual buffer R.  Samples were eluted in 50 µl of best quality 
water.   A second digestion, using EcoRI to linearise the HBV DNA, was performed with a 25 µl 
aliquot of the HindIII elution.  The digestion mix included 1 U EcoRI (Fermentas, MD, USA) per 
µg of DNA, and 1 EcoRI buffer (Fermentas, MD, USA).  Samples were incubated at 37°C for 1 
hour, followed by heat inactivation at 65°C.   Dige sted samples were stored at -20°C. 
 
Plasmid-Safe™ATP-dependent DNase treatment for the isolation of cccDNA 
Plasmid-safe™ ATP-dependent DNase (Epicentre Biotechnologies, WI, USA) was used to 
degrade genomic DNA, rcDNA, HBV dsDNA and HBV ssDNA within the HBV transgenic mouse 
liver and HepG2.2.15 cell extracts.  The samples were digested in a solution containing the 
following components: 25 mM ATP, 2.5µl Reaction buffer (330 mM Tris-acetate (pH 7.8), 660 
mM potassium acetate, 100 mM magnesium acetate, and 5.0 mM dithiothreitol (DTT), 5 U 
Plasmid-safe™ DNase (Epicentre Biotechnologies), within a total volume of 50 µl in a 1.5 ml 
microcentrifuge tube.  The samples were incubated at 37°C for 30 minutes, and analysed by 
means of Southern blot hybridisation and qPCR. 
 
2.4.5   Ethanol precipitation to increase HBV DNA concentrations 
 
HBV DNA was concentrated using alcohol (isopropanol and ethanol) precipitation with 
resuspension in a small volume after HindIII digestion. This was to aid in HBV DNA detection 
during Southern blot hybridisation.  Briefly, 10 µl of 3 M sodium acetate was gently mixed into 
100 µl of the HBV DNA elution, followed by 100 µl of 100% isopropanol, in a 1.5 ml 
microcentrifuge tube.  Elutions were subjected to centrifugation at 12 000  g, for 20 minutes at 
4°C.  The supernatant was discarded and the pellet was gently washed in 50 µl of 70% ethanol, 
by spinning the ethanol through the pellet for 2 minutes at 10 000  g.  This was repeated three 
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times.  The supernatant was removed and the pellet was air dried at 40°C until all residual 
ethanol had evaporated.   Finally the DNA pellet was resuspended in 50 µl of best quality water. 
 
 
2.5  Design of total HBV DNA and cccDNA qPCR primers  
 
2.5.1   HBV genomes and primer synthesis 
 
The cccDNA and total HBV DNA primers were designed using the HBV subtype A1 complete 
genome sequence (NCBI accession number AY738139), as well as the HBV plasmids pCH-
9/3091 and pHBV 1.3 (described in section 2.1.1).  The 3’ ends of the primers were designed 
to have complete sequence complementarity to the target for efficient primer binding and 
amplification.  Primer designs were analysed and validated using Net Primer (PREMIER 
Biosoft International), and nucleotide basic local alignment search tool (BLAST).  
Oligonucleotide primers were synthesised using standard phosphoramidite chemistry 
(Integrated DNA Technologies, Coralville, IA, USA and Inqaba Biotec). 
 
2.5.2   Total HBV DNA (rc/cccDNA) primer set 
 
DNA primers used to detect total HBV DNA were designed to amplify the pre-S1 region within 
the HBV genome.  The primer set includes: rc/cccDNA-F – 5’ TTA TTA TCC AGA ACA TGT 
AGT TAA TCA TTA CTT CC 3’ (forward) and rc/cccDNA-R – 5’ TTG ATG GGA TTG AAG TCC 
CAA TCT GGA TT 3’ (reverse).  The primers bind to HBV subtype A1 (AY738139) between 
nucleotides 2705 to 2971, resulting in a 266 bp product.  In pCH-9/3091, the primer sets 
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amplifies a 256 bp region, from nucleotides 798 to 1054.  In the pHBV 1.3 plasmid, the primers 
amplify between base pairs 1918 and 2184, which results in a 266 bp PCR product.   
 
2.5.3   HBV cccDNA primer set 
 
The cccDNA primers were designed to flank Direct repeat 1 and 2, which in turn will only amplify 
the repaired cccDNA form of the virus as the rcDNA includes a gap region within the 5’ end of 
the negative DNA stand at this point.  The cccDNA primers amplify a portion of the core 
promoter region and the X gene.  The sequences of the HBV cccDNA primer set used for both 
standard PCR and real-time PCR include: cccDNA-F – 5’ TTC TCA TCT GCC GGT CCG TGT 
3’ (forward), and cccDNA-R – 5’ TGG GAC ATG TAC AAG AGA TGA TTA GGC 3’ (reverse).  
The cccDNA primers amplify between the nucleotide base positions 1560 and 1859 of the HBV 
subtype A1 sequence (AY738139), 2842 and 3115 on pCH-9/3091, and lastly between 774 and 
1072 on pHBV 1.3.  Therefore cccDNA amplification should result in a 273 bp and 298 bp 
amplicons in pCH-9/3091 and pHBV 1.3 respectivley.  However as both the HBV plasmids 
include a greater than genome length transcript, they have two core promoter regions. 
Consequently they have an additional cccDNA binding site.  The pHBV 1.3 plasmid has 
additional recognition sites for both cccDNA forward and reverse primers between bases 3994 
and 4268.  Only a second HBV cccDNA-R binding site occurs in pCH-9/3091 at base position 
6297.  As there is no complementary cccDNA forward primer binding site present, only a single 
PCR strand is amplified during PCR. The cccDNA primer binding regions found in pCH-9/3091 
and pHBV 1.3 are illustrated in Figure 2.2.    As a result of the multiple cccDNA primer binding 
sites, absolute quantification of cccDNA was performed using the pTZ-HBVcccR plasmid, as 
described in section 2.1.2.   PCR amplification of the HBV A1 sequence produces a 299 bp 
fragment, whilst amplification of pTZ-HBVcccR results in a 298 bp PCR product.    
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Figure 2.2:  HBV plasmid primer binding positions for the amplification of cccDNA.   A) The cccDNA primer set efficiently 
amplifies a single region of pCH-9/3091, from nucleotides 2842 to 3115 (273 bp).  This amplicon corresponds to the X and pre-core 
protein coding regions.  A second reverse primer binding site occurs at nucleotide base position 6297, however the region amplified 
does not correspond to the correct HBV coding region.  Instead it amplifies the pre-core and core gene sequences which are not 
flanked by the cccDNA forward primer.  B) In pHBV 1.3, there are two cccDNA amplification regions found between nucleotide 
positions 774-1074 (298 bp) and 3994-4268 (274 bp).  Both these regions correspond to the HBx and pre-core ORFs.  It is difficult to 
perform absolute quantification with either of these plasmids, as a single round of PCR would create two different amplification 
products.  The first pHBV 1.3 cccDNA amplicon, located between nucleotide positions 774-1074 was inserted into pTZ-HBVcccR.        
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2.6  Qualitative analysis of HBV primers by conventional PCR and gel 
electrophoresis 
 
HBV cccDNA and total HBV DNA primer sets were evaluated against the two HBV DNA 
plasmids, pTZ-HBVcccR and pCH-9/3091.  The PCR system for cccDNA detection included 
0.5 U GoTaq® DNA polymerase (Promega, Madison, WI, USA), 15 pmol cccDNA-F, 15 pmol 
cccDNA-R, 1 GoTaq® Flexi-Buffer (2 mM MgCl2, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM 
dGTP, 0.2 mM dTTP)(Promega), and 0.1 ng pTZ-HBVcccR to a final volume of 25 µl.  The 
same PCR system used for cccDNA amplification was used for total HBV DNA detection with 
the substitution of the cccDNA primer set with the rc/cccDNA forward and reverse primers, and 
pTZ-HBVcccR with pCH 9/3091, at the same concentrations.  Negative controls were included 
using the same PCR reaction components but with the absence of HBV plasmid DNA.  All 
conventional PCR runs were performed in an Eppendorf Mastercycler gradient thermocycler.  
Cycle parameters included initial denaturation at 95°C for 2 min followed by 25 cycles at 95°C 
for 30 s, 60°C for 30 s, and 72°C for 30 s, and fin al extension at 72°C for 5 min.  PCR products 
were analysed by agarose gel electrophoresis.  Ten microlitre aliquots were mixed with 6  
Loading dye (Appendix 5.2.1), and 10 µl of O’GeneRuler was loaded separately as a DNA 
ladder.  cccDNA amplification products were loaded into a 2% agarose gel containing 0.0025% 
Ethidium Bromide whilst the PCR products from the total HBV DNA amplification were loaded 
into a 1.5% Agarose gel (0.0025% Ethidium Bromide). The samples were subjected to 
electrophoresis for 90 min at 130 V in 1TAE buffer (Appendix 5.2.1).  Gels were analysed 
using the GelLogic 200 imaging system and visualised under UV light for DNA band migration 
with the Kodak 1D image analysis software.   
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2.7  Quantification of total HBV DNA and cccDNA by Lightcycler™ PCR 
 
2.7.1   Total HBV DNA (rc/cccDNA) and cccDNA Real-time PCR standards 
 
Eight-fold log serial dilutions of pTZ-HBVcccR, pTZ-HBVrc/cccR, and pCH-9/3901 were created.  
Triplicates of plasmid serial dilutions were amplified by real-time qPCR using the Lightcycler™ 
2.0 thermocycler, and analysed using the Lightcycler ™ software version 4.0 (Roche 
Diagnostics, Germany).  cccDNA amplification and quantification was performed using the pTZ-
HBVcccR construct as the standard.  The rc/cccDNA-F and rc/cccDNA-R primers were used to 
quantify total HBV DNA, through the amplification of both the pTZ-HBVrcR and pCH-9/3901 as 
plasmid standards.   The Lightcycler™ PCR mix for the quantification of cccDNA or total HBV 
DNA included 4 µl LightCycler® FastStart DNA Masterplus SYBR Green I (Roche Diagnostics, 
Germany), 15 pmol forward primer (either cccDNA-F or rc/cccDNA-F), 15 pmol reverse primer 
(either ccDNA-R or rc/cccDNA-R), and 5 µl of a log serial dilution (102 - 107) of DNA template 
(either pTZ-HBVcccR, pTZ-HBVrcR, or pCH-9/3901), to a final volume of  20 µl in a 
Lightcycler™ glass capillary (Roche Diagnostics, Germany), under sterile conditions.  
Capillaries were centrifuged (in cooled metal capillary adaptors) for 30 seconds at 700  g.  
Capillaries were loaded into the Lightcycler carousel and the samples were amplified under the 
following conditions: hot start at 95°C for 10 min;  50 PCR cycles of 95°C for 10 s, 60°C for 10 s 
and 72°C for 10 s with a single SYBR® Green signal acquisition at this point.  Melting curve 
analysis was performed after the PCR step by heating at 95°C for 0 s, cooling to 65°C for 1 min, 
and raising the temperature to 95°C at a ramp of 0. 1°C/s with continuous SYBR® Green signal 
acquisition.  Standard curves were constructed for each of the dilution series samples, in 
triplicate, based on their relative crossing points (CP).  Each log dilution had a particular 
threshold CT, or CP, which corresponded to the cycle at which the sample first enters 
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exponential amplification, and the fluorescence emitted is greater than that of the background 
fluorescence.  The CP points were plotted against the known DNA concentrations provided by 
the dilution series to create a linear standard curve. Melting curve analysis was performed to 
assess the specificity of the amplification reaction and to monitor for contamination.   A 
minimum detection limit was assigned for cccDNA quantification and total HBV DNA 
quantification based on the standard curves.  The plasmid concentrations in each dilution were 
converted to plasmid copy numbers using the following equation:  
 
Number of copies = (mass x 6.022x1023) / (length x 1x109 x 650) 
 
Where the mass is the amount of plasmid in nanograms and length is the size of the plasmid in 
base pairs.  This calculation is based on the assumption that a single base pair has a molecular 
weight of 650 Da.  The derivation of the above equation is from first principles, as described 
below.   
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2.7.2   Lightcycler™ quantification of HBV DNA from 
HBV transgenic mouse 
 
DNA extracted from HBV transgenic mouse samples and HepG2.2.15 cell samples
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dilutions of pTZ-HBVcccR were run as positive controls for cccDNA quantification, whilst pTZ-
HBVrcR and pCH-9/3901 were run as positive controls for total HBV DNA quantification.  The 
qPCR components for cccDNA, total HBV DNA and St6gal1 detection included 4 µl 
LightCycler® FastStart DNA Masterplus SYBR Green I, 15 pmol forward primer (either cccDNA-
F, rc/cccDNA-F, or St6gal1-F), 15 pmol reverse primer (either ccDNA-R, rc/cccDNA-R or 
St6gal1-R), and 5 µl of DNA sample (either HBV mouse liver, HBV mouse serum, HepG2.2.15 
cells, HepG2.2.15 media supernatant, mouse genomic DNA,  pTZ-HBVcccR, pTZ-HBVrcR, or 
pCH-9/3901) to a final volume of 20 µl in a glass Lightcycler™ capillary.  PCR cycling conditions 
were the same as those described in section 2.7.1.   To quantify rcDNA, the total number of 
cccDNA copies/µl was subtracted from total HBV DNA copies/µl, to give the exact amount of 
cccDNA and rcDNA in each sample.  
 
 
2.8  Determining HBV RNAi-knockdown efficiency and monitoring of 
transgene delivery through psiCHECK2.2 
 
2.8.1. Murine hydrodynamic tail injection 
 
The knockdown efficiency of RNAi-based, anti-HBV gene silencing was assessed using the 
HBV qPCR assay.  Murine hydrodynamic tail vein injections (Liu et al., 1999) were used to 
administer an HBV replication-competent plasmid (Yang et al., 2002), linear cassettes, and miR-
expression plasmids.  The anti-HBV sequences used were miR- expression plasmids containing 
U6 shRNA5 (Carmona et al., 2006) or miR-122/5 (Ely et al., 2008), and linear cassettes 
comprising Lin-122/5 or ITR-122/5 (Chattopadhyay et al., 2009).  A transgene delivery control 
plasmid, psiCHECK2.2 (Ely et al., 2008), was included in each hydrodynamic injection to 
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monitor liver specific transgene delivery.   The plasmid DNA solution used for assessing RNAi-
knockdown efficiency included: 5 µg pCH-9/3091, 5 µg RNAi expression cassette (pU6 shRNA 
5, pCMV miR-122/5, Lin-122/5, or ITR-122/5), and 5 µg psiCHECK2.2.   A mock (containing 5 
µg pCH-9/3091, 5 µg pCI-neo backbone, and 5 µg psiCHECK2.2) as well as a negative control 
(containing only 5 µg psiCHECK2.2) were also included.    
 
2.8.2. Quantification of total HBV DNA and RNA from mouse hydrodynamic 
injection serum and liver samples 
 
To determine the effects of RNAi and linear cassettes on HBV circulating virions and 
intrahepatic HBV DNA and RNA levels, total DNA and RNA was extracted from mouse serum 
and liver samples respectively.  Murine blood samples were collected by means of retro-orbital 
bleeding, at days 3 and 5 post injection.  Total DNA was isolated from   30 µl of serum using the 
QIAmp® DNA Blood Mini Kit as previously described in section 2.2.1.  Serum HBV DNA was 
quantified using real-time qPCR, as depicted in section 2.7.2.  Total RNA was extracted from 
100 mg of homogenised mouse liver according to the guanidine single-step RNA isolation from 
cultured cells and tissues (Chomczynski, 1996) as shown in Appendix 5.2.6, followed by reverse 
transcription of the RNA to cDNA using the QuantiTect reverse transcription kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions (Appendix 5.2.7). The qPCR 
components for HBV cDNA detection included 4µl LightCycler® FastStart DNA Masterplus SYBR 
Green I, 15 pmol forward primer (rc/cccDNA-F), 15 pmol reverse primer (rc/cccDNA-R), and 5 µl 
HBV mouse liver, to a final volume of 20 µl with best quality water in a glass Lightcycler™ 
capillary. HBV RNA was quantified relative to murine glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA using the following primers:  GAPDH-forward 5'- TTC ACC 
ACC ATG GAG AAG GC -3' and GAPDH-reverse 5'- GGC ATG GAC TGT GGT CAT GA -3' 
(Song E et. al, 2005).  Negative controls included water blanks and RNA samples not subjected 
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to reverse transcription.  Thermocycling parameters were the same as those depicted in section 
2.7.2.   Intrahepatic DNA was isolated from 50 mg of homogenised mouse liver as described in 
section 2.2.1, and analysed by qPCR as described in section 2.7.2.   
 
2.8.3. Renilla luciferase real-time qPCR standards 
 
The Renilla luciferase gene, present in psiCHECK2.2, was chosen as a qPCR amplification 
target for monitoring the efficacy of transgene delivery after hydrodynamic injection.  The Renilla 
luciferase primers, Rluc-F (1031-1057): 5’ AAA TCA TCT TTG TGG GCC ACG ACT GG 3’ 
(forward) and Rluc-R (1263-1290): 5’ GAA CTC CTC AGG CTC CAG TTT CCG CAT 3’ 
(reverse), amplify a 260 bp region of the psiCHECK2.2 plasmid.  Primer designs were analysed 
and validated using Net Primer (PREMIER Biosoft International) and synthesised by standard 
phosphoramidite chemistry (Inqaba Biotec).     
 
A nine fold log serial dilution of psiCHECK2.2 was used to create a Renilla luciferase real-time 
qPCR standard curve.  The Lightcycler™ PCR components and thermocycling conditions, using 
the Renilla luciferase primer set, were the same as those described in section 2.7.1.  To 
determine whether the standard curve constructed was of high-quality, the efficiency and linear 
regression error scores were analysed. The minimum detection limit was set at 85 copies of 
Renilla luciferase.    
 
 
2.9  Multiple Alignments 
 
To determine whether the total HBV DNA and cccDNA primer sets are universal, a multiple 
alignment was performed using the HBV A1 genotype from Uganda (NCBI accession number: 
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AY934772), Gambia (NCBI accession number: AY934764), and Germany (NCBI accession 
number: AY738139) (Appendix 5.3).  The multiple alignments were evaluated using the AlignX 
software from the Vector NTI suite 9.0.0 (Invitrogen, MD, USA).     
 
 
2.10  Statistical Analysis 
 
All Southern blot and qPCR quantification was performed in triplicate, for each sample type, 
condition, and/or treatment performed, unless otherwise stated. Data is represented as the 
mean ± the standard error of the mean (SEM).  Two-tailed paired and unpaired Student’s t tests 
were performed using GraphPad Prism version 4.00 (GraphPad software, San Diego, 
California, USA).  P values of < 0.05 were regarded as statistically significant.   
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CHAPTER  3  –  RESULTS 
 
3.1  Real-time qPCR is capable of independently quantifying total HBV DNA 
and cccDNA 
 
The two major forms of HBV DNA, the rcDNA and cccDNA, share extensive sequence 
homology, differing only by the incomplete nature of rcDNA’s positive strand and gap region.  To 
differentiate between these two DNAs during PCR analysis, HBV cccDNA primers were 
designed to exclusively amplify the cccDNA form of the virus.  Total HBV DNA (rc/cccDNA) 
primer set amplifies a portion of the polymerase and pre-S1 region, which is common to both 
HBV DNAs.  Figure 3.1 highlights fundamental differences between the two forms of HBV DNA, 
as well as the orientation of both primer sets.  cccDNA primers flank the Direct Repeats (He et 
al., 2002), which encompass the 5’ gap region of the HBV DNA negative strand.  As this gap 
region is present in rcDNA, but repaired in cccDNA, the primers only efficiently amplify cccDNA.  
Any PCR amplification of the rcDNA gap region should result in truncated amplicons.  
Additionally, the cccDNA forward primer was designed to bind 30 bases upstream of DR2, 
which coincides with the 5’ RNA end of the HBV rcDNA positive strand.  This inhibits forward 
primer binding and exponential amplification of truncated PCR products.  Using these primer 
sets to create cccDNA and total HBV DNA standard curves, HBV DNA can be quantified from 
various sources by qPCR. 
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Figure 3.1: Schematic illustration of HBV rcDNA and cccDNA including specific qPCR primer binding sites.  DR1 and DR2 
are found in both the rcDNA and cccDNA forms of HBV, as indicated in blue.  In rcDNA, DR1 and DR2 flank the 5' negative strand 
gap region which has subsequently been repaired in the cccDNA species.  Additionally the positive DNA strand is only partially 
synthesised in the rcDNA but is complete in cccDNA. The cccDNA primers, shown in yellow, flank the Direct Repeats, which 
encompasses the gap region.  The total HBV DNA (rc/cccDNA) primers, shown in red, are found further upstream and amplify 
sequences of the polymerase and pre-S1 ORFs of HBV. 
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3.1.1   pTZ-HBVcccR contains a single copy of the HBV pre-core region 
 
Replication-competent HBV plasmids contain a greater than genome length version of viral 
DNA, allowing pgRNA to be transcribed.  As a result of this, both pCH-9/3091 and pHBV 1.3 
contain two copies of the HBV pre-core ORF, and consequently two cccDNA primer binding 
regions.  As neither pCH-9/3091 nor pHBV 1.3x could be used to accurately determine cccDNA 
copy number, a pTZ57T/R based plasmid clone, containing a single copy of the cccR, was 
constructed.  An rcR plasmid was also constructed as a total HBV DNA control (Figure 2.1).      
The cccR and rcR regions were amplified from pCH-9/3091 and pHBV 1.3 .  Initially 
conventional PCR amplification of the cccR resulted in additional bands.  This was as a result 
of the primers circularising the greater than genome length HBV transcript, caused by the 
presence of two HBV core regions. Therefore, bands corresponding to the correct cccR and 
rcR amplicon sizes, were excised, extracted, and re-amplified.  This resulted in a single 
amplification product which was cloned into pTZ57T/R.  To confirm the presence of the cccR 
and rcR inserts, restriction digests were performed. 
 
Two independent restriction digests were used to determine if the cccR and rcR inserts were 
successfully cloned into pTZ57T/R, as well as to determine their orientations (Figures 3.2 and 
3.3).  The first restriction digest, a double digestion including XbaI and BamHI, was used to 
confirm the presence of the inserts within the selected clones.  Both XbaI and BamHI restriction 
sites directly flank the pTZ57T/R MCS.  A double digestion of pTZ-HBVcccR and pTZ-HBVrcR 
resulted in DNA bands of 425 bp and 395 bp, corresponding to the cccR and rcR respectively.   
This confirms the presence of the inserts within the plasmids.  A second restriction digestion, 
with EcoRI, was used to indicate whether the inserts were in a positive orientation.  This is 
attributed to an EcoRI restriction site within pTZ57R/T plasmid, at base position 615, which 
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precedes the multiple cloning site.  A second EcoRI restriction site was incorporated into the 5’ 
ends of the cccR and rcR reverse primers.  If the HBV DNA insert is in the positive orientation, 
an EcoRI restriction digest will, theoretically, result in a cccR and rcR insert of 450 bp and 419 
bp respectively.  However if a transcript of 39 bp or less is observed, a negative orientation is 
assumed. 
 
As shown, in Figure 3.3, all the clones were found to contain either the cccR or rcR insert, 
however mostly in the negative orientation.  Although the majority of the clones were in the 
negative orientation, this does not affect real-time PCR. Therefore pTZ-HBVcccR clone iii (lane 
14) and pTZ-HBVrcR clone number 1 (lane 17) were selected for the real-time PCR assays.  
The pTZ-HBVcccR clone was found to have an elution concentration of 162.2 ng/µl whilst the 
pTZ-HBVrcR clone has a final concentration of 147.6 ng/µl.  To further validate the pTZ-
HBVcccR construct, the plasmid was sequenced (Appendix 5.1.3).  The pTZ-HBVcccR plasmid 
was used to construct a cccDNA real-time qPCR standard curve.   This construct is essential 
for the accurate quantification of cccDNA during real-time PCR, as it contains only one copy of 
the X protein and pre-core coding regions, unlike the greater than genome length plasmids 
pCH-9/3091 and pHBV 1.3. 
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Figure 3.2: Positive and negative orientations of pTZ-HBVcccR and pTZ-HBVrcR.  The cccR and rcR PCR products were 
cloned into pTZ57R/T.  ORFs transcribed in the same direction as the T7 promoter (P T7) are in the positive orientation.  A single 
inherent EcoRI site flanks the MCS whilst a second restriction site is generated during PCR amplification of the cccR or rcR ORFs. 
Orientation is resolved, by fragment size, subsequent to restriction digestion. 
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Figure 3.3:  Restriction digest of pTZ-HBVcccR and pTZ-HBVrcR clones.  Five pTZ-HBVcccR clones (i, ii, iii, iv, v) and five pTZ-
HBVrcR clones (1, 2, 3, 4, 5) were chosen for restriction digest screening.  All plasmids are positive for XbaI/BamHI restriction 
digestion, based on the presence of a 450 bp band in pTZ-HBVcccR clones and a 419 bp band in pTZ-HBVrcR clones.  A truncated 
product was observed for pTZ-HBVcccR clone i, which was subsequently eliminated from plasmid selection.  The only clone positive 
for EcoRI double digestion is pTZ-HBVrcR clone 2, indicating the pre-S1 insertion is in the positive orientation.  All remaining clones 
are in the negative orientation.  Two clones, pTZ-HBVcccR iii and pTZ-HBVrc 1, were selected for qPCR analysis.    
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3.1.2   Primers designed for qPCR efficiently amplify HBV plasmid DNA using   
   conventional PCR  
 
Conventional PCR amplification together with agarose gel electrophoresis was used to 
determine the efficacy of both HBV primer sets.  pTZ-HBVcccR and pCH-9/3091 acted as 
templates for cccDNA and total HBV DNA primers respectively.  As shown in Figure 3.4, single 
amplicons were produced during both PCR assays, indicating that the primers bind exclusively 
to their designed targets.  The post-PCR electrophoretic bands observed for pTZ-HBVcccR and 
pCH-9/3091 correlate with predicted amplicon sizes.  cccDNA primers result in a band of 
approximately 300 bp, which equates to the 298 bp pTZ-HBVcccR target amplicon (Figure 
3.4a), whilst total HBV DNA primers amplify a 256 bp region of pCH-9/3091, observed between 
the 200 and 300 bp molecular weight markers (Figure 3.4b).  Primer-dimers, less than 100 bp in 
length, were observed at a very low intensity.  Therefore, HBV qPCR primers efficiently amplify 
target DNA sequences. In addition to the PCR assays, a multiple alignment of various HBV A1 
genotypes and pTZ-HBV cccR were assayed for efficient cccDNA primer binding.  As shown in 
Figures 3.5 and 3.6, HBV A1 isolates and plasmid vectors have sufficient primer 
complementarity, specifically at the 3’ ends, to amplify a range of HBV target sequences.  HBV 
plasmid vectors were subsequently used to create qPCR standard curves.  
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Figure 3.4: HBV qPCR primers amplify target sequences.  Conventional PCR and agarose 
gel electrophoresis confirms single amplification products for both cccDNA and total HBV DNA 
primer sets.  A) pTZ-HBVcccR was used as a cccDNA template.  PCR amplification results in a 
298 bp amplicon.  B) Total HBV DNA primers solely amplify a 256 bp region of the pre-S1 ORF 
in pCH-9/3091.  Water blanks were included during both PCR assays as negative controls.   
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                cccDNA -F     (1) ---------TTCTCATCTGCCGGTCCGTGT-------------------- 
 HBV A1 Uganda (AY934772)  (1551) GTCTGTGCCTTCTCATCTGCCGGTCCGTGTGCACTTCGCTTCACCTCTGC 
 HBV A1 Gambia (AY934764)  (1551) GTCTGTGCCTTCTCATCTGCCGGACCGTGTGCACTTCGCTTCACCTCTGC 
HBV A1 Germany (AY738139)  (1551) GTCTGTGCCTTCTCATCTGCCGGTCCGTGTGCACTTCGCTTCACCTCTGC 
               pCH-9/3091  (2833) GTCTGTGCCTTCTCATCTGCCGGACCGTGTGCACTTCGCTTCACCTCTGC 
                pHBV 1.3x  (3985) GTCTGTGCCTTCTCATCTGCCGGTCCGTGTGCACTTCGCTTCACCTCTGC           
              pTZ-HBVcccR   (668) GTCTGTGCCTTCTCATCTGCCGGTCCGTGTGCACTTCGCTTCACCTCTCC         
                Consensus         GTCTGTGCCTTCTCATCTGCCGGTCCGTGTGCACTTCGCTTCACCTCTGC 
                                                                             
 
 
 
Figure 3.5: cccDNA forward primer has extensive sequence complementarity.  All three HBV A1 sub-genotypes show high 
complementarity between the various HBV plasmid sequences, specifically pTZ-HBVcccR.  The blue highlighted regions indicate 
highly complementary regions whilst the yellow highlights indicate completely complementary sequences.  A single polymorphism (T 
to A) is common to both the HBV A1 Gambian strain and pCH-9/3091.   
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                 cccDNA-R     (1) -----------------GCCTAATCATCTCTTGTACATGTCCCA----- 
 HBV A1 Uganda (AY934772)  (1786) GCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACTGTT 
 HBV A1 Gambia (AY934764)  (1786) GCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACTCTT 
HBV A1 Germany (AY738139)  (1786) GCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACTGTT 
               pCH-9/3091  (3099) CAACTTTTT-CACCTCTGCCTAATCATCTCTTGTTCATGTCCTACTGTTC 
                pHBV 1.3x  (4251) CAACTTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACTGTTC                
              pTZ-HBVcccR  (1034) CAACTTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCTACTGTTC 
                Consensus         GCGCACCAGCACCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTA 
                                                                           
           
 
Figure 3.6: Multiple alignment of cccDNA reverse primer.   There is extensive sequence complementarity, specifically at the 3’ 
end of the cccDNA-R primer to effectively amplify all three HBV A1 subgenotypes and viral plasmids.  Blue highlighted sequences 
indicate highly complementary regions whilst yellow highlighted sequences indicate complete complementarity.  Two polymorphisms, 
A to T and C to T, are present in pCH-9/3091 whilst pTZ-HBVcccR contains a single base change at nucleotide position 1077 (C to 
T). Although pTZ-HBVcccR does not show complete sequence complementarity at the 5’ end, this does not affect PCR amplification 
efficiency.       
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3.1.3   Construction of Real-time qPCR standard curves for HBV DNA  
   quantification 
 
Real-time standard curves, essential for the accurate quantification of viral DNA, were created 
for cccDNA and total HBV DNA.  Eight-fold log serial dilutions of pTZ-HBVcccR and pCH-
9/3091 were used for the construction of HBV standard curves (Figure 3.7).  pTZ-HBVcccR 
concentrations ranged from 0.33 ng/µl to 3.3  10-8 ng/µl, whilst pCH-9/3091 concentrations 
ranged from 5.8 ng/µl to 5.833  10-7 ng/µl.  Water blanks and mouse genomic DNA were 
included as negative PCR and HBV controls respectively.  To construct these curves the CP 
values were plotted against their relative log concentrations.  Standard curves and internal 
controls were used during HBV qPCR analysis to accurately quantify both forms of viral DNA.  
Although it is useful to describe initial DNA quantities as nanogram concentrations, for HBV 
DNA analysis the number of DNA copies would provide a more practical representation of viral 
infection.  In particular, the number of HBV DNA copies per hepatocyte is useful when 
describing the degree of HBV infection.        
 
Plasmid DNA concentrations can be mathematically adjusted to represent the initial number of 
DNA copies per sample, as described in section 2.7.1.  Therefore, standard curves were 
constructed to represent the CP values versus DNA copy number.  By using DNA copy 
numbers instead of concentrations, the number of HBV DNA copies per sample can be 
accurately determined.  The cccDNA standard curve is able to detect up to 9.24   107 
copies/µl with an efficiency of 2.0 (100%) and error rate of 0.0229, whereas the total HBV DNA 
standard curve detects up to 8.48  108 copies/µl with an efficiency of 1.86 (93%) and error 
rate of 0.0255.  PCR efficiency is an important factor to consider during absolute quantification 
as it reveals whether exponential amplification is achieved throughout analysis.  Non-optimal 
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reagents or cycling conditions can affect this resulting in inaccurate quantification, specifically 
at higher CP values.  Efficiency normally ranges between 1.5 and 1.9, with a maximum value of 
2.0 (Wilhelm and Pingoud, 2003).  Both the cccDNA and total HBV DNA standard curves have 
a high degree of efficiency indicating optimal qPCR conditions.  
 
Minimum detection limits were established for HBV qPCR assays, as it became difficult to 
determine the differences between primer dimer formation and single amplification products at 
very low concentrations of plasmid DNA.  Additionally, by including these limits in subsequent 
qPCRs, the detection of false-positives was prevented.  Total HBV DNA and cccDNA qPCR 
analyses had minimum detection limits of 84 and 10 copies respectively.  The ability of this 
assay to detect very low levels of cccDNA is imperative, as this form of HBV DNA is often 
present at clinically undetectable levels during implementation of therapeutic regimens or 
occult infections.  It is also important that cccDNA primers do not amplify rcDNA as this would 
result in an inaccurate resolution of the HBV DNA profile.  
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Figure 3.7: Real time PCR amplification and standard curves for pCH-9/3091 and pTZ-HBVcccR dilution series.  Standard 
curves for total HBV DNA (rc/cccDNA) and cccDNA were constructed using the HBV greater than genome length plasmid, pCH-
9/3091 (A) and cloned plasmid, pTZ-HBVcccR (B). Each standard curve was constructed from an 8-fold log serial dilution of the 
representative plasmid (n=3).  High efficiencies, of 2.0 and 1.86, were observed for both the cccDNA and total HBV DNA 
respectively.   
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3.1.4   cccDNA primers do not amplify across the gap region of rcDNA 
 
As both the cccDNA and rcDNA forms of HBV DNA share complete sequence homology, the 
precise amplification of cccDNA relies on the rcDNA gap region halting polymerase activity 
during qPCR.  To ensure that cccDNA primers do not amplify rcDNA non-specifically three 
separate qPCRs were performed.  The first with an HBV Eurohep standard (WHO international 
standard), the second using whole virion extracts, and the third to assess the need for viral DNA 
extraction.  Figure 3.8 shows the amplification and melting curve analysis obtained with the 
Eurohep standard, confirming that cccDNA primers do not amplify rcDNA, whereas total HBV 
DNA primers do.  Eurohep melting peaks observed during cccDNA primer amplification 
correspond only to the water blank, indicating no HBV amplification.  Total HBV DNA primers on 
the other hand amplify the Eurohep standard, and display melting peaks equivalent to the pCH-
9/3091 positive control.  To corroborate these results, whole virions were isolated from HBV 
transgenic mouse serum before DNA extraction and qPCR analysis. As whole virions enclose 
only rcDNA, any circulating cccDNA will be excluded from the extraction during virion isolation.  
cccDNA was not detected above the minimum detection limit in serum virion isolated samples 
(Figure 3.9) whereas rcDNA was readily quantified (by subtracting the cccDNA from total HBV 
DNA).  Furthermore, to illustrate that cccDNA was not merely absent from these samples, DNA 
extraction was found to be a prerequisite when quantifying both forms of HBV DNA.          
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Figure 3.8: Eurohep standard qPCR assay amplification and melting curve analysis.  A) Amplification curves of Eurohep 
standards with cccDNA and total HBV DNA primer sets.  cccDNA primers are unable to amplify the rcDNA present in the Eurohep 
HBV standard, compared to pTZ-HBVcccR which was used as a positive control.  The total HBV DNA primers amplify the Eurohep 
standard as well as the pCH-9/3091 positive control.  B) Melting curve analysis indicates cccDNA primers do not amplify rcDNA, as 
Eurohep and water primer dimers are observed together at 81°C, when using cccDNA primers.  qPCR with t otal HBV DNA primers 
resulted in amplification of the pCH-9/3091 positive control and the Eurohep HBV standard at 84°C and 85°C respectively.  Primer 
dimers are present in both the water blank and to some extent in the Eurohep standard between 73 - 76°C.  
A) B) 
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Figure 3.9: cccDNA primers do not amplify rcDNA during qPCR.  HBV transgenic mouse 
serum rcDNA, confined within whole virions, was analysed by real-time qPCR.  cccDNA and 
total HBV DNA primers were used to quantify both forms of HBV DNA.  pTZ-HBVcccR and 
pCH-9/3091 acted as positive controls and internal standards.  The HBV serum samples contain 
a total HBV DNA average of 4.800  103 copies/µl.  The minimum detection limit for cccDNA 
quantification (as illustrated on the graph) is 10 copies; however HBV serum contained an 
average of only 7.29 copies/µl of cccDNA which is most likely an indicator of primer dimers.  
Consequently, rcDNA was found to be the predominant form of HBV DNA at an average of 
4.792  103 copies/µl.  Error bars indicate SEM of n=4.      
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To accurately quantify total HBV DNA loads, encapsulated rcDNA requires a DNA extraction 
step to free the viral genome and allow it to be amplified by qPCR.  Serum cccDNA on the other 
hand, circulates as ‘naked’ DNA and can be amplified from samples without DNA extraction.  To 
determine whether cccDNA primers amplify rcDNA and if DNA extraction protocols are essential 
for total HBV DNA quantification, HepG2.2.15 cell supernatants were analysed by qPCR.  
HepG2.2.15 cells contain a stably integrated HBV genome.  As such, they constantly produce 
new HBV virions.   Table 3.1 displays the mean cccDNA and total HBV DNA copy numbers 
observed.  Log serial dilutions of pTZ-HBVcccR and pCH-9/3091 were included as internal 
standards. Figure 3.10 shows that DNA extraction is a critical process required for total HBV 
DNA quantification as non-extracted HepG2.2.15 supernatants are unable to amplify rcDNA, 
and thus underestimate the amount of total viral DNA present in the sample.  Extracted 
HepG2.2.15 supernatants on the other hand, show that rcDNA is the predominant form of viral 
DNA.  This is to be expected as newly synthesised virions harbouring rcDNA are released into 
the supernatant.  Furthermore this qPCR shows that cccDNA primers do not amplify rcDNA, as 
there is no statistical difference between the amount of cccDNA present in the non-extracted 
supernatants versus total HBV DNA (p-value = 0.7922), however there is a significant difference 
between the amounts of cccDNA and total HBV DNA in the extracted sample (p-value = 
0.0016), indicating that rcDNA is present and efficiently amplified.  Although cccDNA was 
isolated from the HepG2.2.15 in vitro culture system, this is only clinically observed during 
hepatocellular death and liver damage associated with chronic HBV infection.  As this qPCR 
assay allows for the efficient amplification of both forms of viral DNA, the HBV DNA profiles of in 
vitro and in vivo samples can be analysed.  Overall, viral DNA extraction is essential for the 
accurate measurement of HBV viral loads, specifically in serum samples where circulating viral 
particles predominate.    
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Table 3.1: Quantification of HBV DNA from HepG2.215 cell culture 
HepG2.2.15 Supernatant HBV DNA copies/µl*(SEM) p-value** 
 cccDNA Total HBV DNA  
Extracted 1650 (12) 29367 (1129) 0.0016** 
Non-Extracted 739 (48) 749 (72) 0.7922 
 
*mean value (n=3) 
** statistical significance < 0.05 (5%)  
 
 
 
 
 
Figure 3.10: DNA extraction is a prerequisite for HBV qPCR analysis.  HepG2.2.15 
supernatants contain both cccDNA and rcDNA forms of HBV.  Extracted samples contain an 
average of 29367 copies of total HBV DNA of which only 6% is cccDNA.  Non-extracted 
samples contain 749 copies of total HBV DNA comprising mainly cccDNA (99%).  Only 
extracted samples were able to quantify rcDNA bellow the detection limit.  Samples analysed in 
triplicate and error bars indicate SEM.  
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3.1.5   Absolute quantification of total HBV DNA and cccDNA from in vitro and in  
   vivo HBV model systems 
 
The HBV DNA profiles of HepG2.2.15 cell culture systems and HBV transgenic mice were 
evaluated using Lightcycler™-based qPCR. Absolute quantification of HBV DNA from 
HepG2.2.15 cells and culture supernatants as well as HBV transgenic mouse liver and serum 
samples, was achieved through the simultaneous analysis of HBV plasmid standards as 
positive controls and internal references.  Three different log serial dilutions of pTZ-HBVcccR 
and pCH-9/3091 were used to establish cccDNA and total HBV DNA copy numbers 
respectively.  Water blanks and mouse genomic DNA samples (191.6 ng/µl), were included as 
negative controls.  As previously described (Section 3.1.3) the minimum detection limit for 
cccDNA quantification is 10 copies compared to total HBV DNA with 84 copies.  Preliminary 
qPCR of HBV transgenic mouse liver displayed large amounts of HBV DNA which were difficult 
to accurately quantify.  Therefore all liver samples were diluted 1:2 prior to qPCR, but 
quantification values were adjusted accordingly during post-PCR analysis.   
 
During each PCR reaction, melting curve analysis was performed to assess specificity of 
amplification.  Accurate qPCR quantification was confirmed with melting curves of 84°C for total 
HBV DNA and 87°C for cccDNA.  The in vitro and in vivo HBV DNA concentrations obtained by 
qPCR are shown in Table 3.2.   HBV primers were incapable of amplifying non-transgenic 
mouse genomic DNA, demonstrating that any co-precipitated genomic DNA did not affect HBV 
quantification.  Although transgenic mouse genomic DNA contains two integrated copies of the 
HBV viral genome within in each hepatocyte, amplification of these integrated transcripts 
accounts for, at most, only 1% of total HBV DNA and 2.5% of cccDNA detected by qPCR.  The 
HepG2.2.15 cell extracts show the highest total HBV DNA quantities followed by HBV 
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transgenic mouse liver, HepG2.2.15 supernatant, and lastly HBV transgenic mouse serum.  
Transgenic mouse liver has the greatest proportion of cccDNA, followed by HepG2.2.15 cells.  
This is to be expected as cccDNA resides in the nucleus of hepatocytes.  rcDNA remains the 
most prominent form of HBV DNA in all samples, indicating active replication.  Although rcDNA 
predominates in HepG2.2.15 cell and supernatant samples, transgenic mouse livers were found 
to contain a high percentage of cccDNA, indicating that rcDNA may be recycled and translocate 
to the nucleus of murine hepatocytes (illustrated in Figure 1.2).  Figures 3.11 and 3.12 display 
the HBV DNA profiles of transgenic mice and HepG2.2.15 samples.  HBV transgenic mouse 
liver consists of 40% cccDNA and 60% rcDNA whilst serum contains only 3% cccDNA and 97% 
rcDNA.  HepG2.2.15 cell cultures predominantly contain rcDNA, at 98% in cell extracts and 
100% in supernatants.  Despite the vast differences in HBV DNA profiles, both the transgenic 
mice and HepG2.2.15 cell cultures harbour similar amounts of cccDNA.  HepG2.2.15 cells 
however, produce and release vast quantities of rcDNA compared to the mouse model.  
 
This HBV qPCR assay results in the sensitive detection of both rcDNA and cccDNA species, 
demonstrating its capacity for monitoring HBV DNA.  Although qPCR is widely used for viral 
DNA quantification, Southern blot hybridisation is considered the ‘gold standard’ for HBV DNA 
detection and analysis.  Therefore HBV qPCR results were validated using non-radioactive 
Southern blot hybridisation. 
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Table 3.2: Absolute quantification of HBV DNA through Lightcycler™ qPCR 
 HBV DNA copies per assay (SEM) 
 cccDNA Total HBV DNA rcDNA* 
pTZ-HBVcccR 9.25  104 - - 
pCH-9/3091 - 8.48  105 - 
HBV Transgenic Mouse Liver** 9.90  105 (1.36  105) 2.46  106 (8.33  104) 1.47  106 (2.05  105) 
HBV Transgenic Mouse Serum** 227 (16) 6637 (451) 6410 (463) 
HepG2.2.15 Cells** 1.34  105 (4.10  103) 8.83  106 (5.57  104) 8.70  106 (5.30  104) 
HepG2.2.15 Supernatant** 478 (6) 2.36  105 (3.28  104) 2.36  105 (3.29  104) 
 
*Determined by subtracting cccDNA from total HBV DNA 
**mean values (n=3) 
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Figure 3.11: HBV DNA profiles of transgenic mice.  Total HBV DNA and cccDNA 
quantification was performed on DNA extracted from the livers and serum of HBV transgenic 
mice.  pTZ-HBVcccR and pCH-9/3091 were included as positive controls and standard 
references.  Transgenic liver samples contained an average of 2.46  106 copies of HBV DNA, 
of which 40% was cccDNA.  Considerably less viral DNA was isolated from serum, where 
cccDNA only constitutes 3% of the 6637 copies of total HBV DNA.  No HBV DNA was detected 
in mouse genomic DNA samples.  Error bars indicate the SEM (n = 3).  
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Figure 3.12: In vitro quantification of HBV DNA.  HepG2.2.15 cell cultures were analysed by 
qPCR to establish the HBV DNA profiles of cell extracts and supernatants.  pTZ-HBVcccR and 
pCH-9/3091 were included as positive controls (data not shown).  Both HepG2.2.15 cell extracts 
and supernatants retain significantly large amounts of total HBV DNA with 8.83  106 and 2.36 
 105 copies respectively.  Of this, rcDNA remains the major form of viral DNA, accounting for 
98% of total HBV DNA isolated form cells and 100% isolated from supernatant.  HepG2.2.15 
samples were analysed in triplicate and error bars indicate the SEM.   
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3.2  Non-radioactive Southern blot hybridisation is proficient at detecting HBV 
DNA 
 
Southern blot hybridisation has been extensively used to quantify total HBV DNA as well as 
isolate rcDNA and cccDNA from replicative intermediates (Farza et al., 1988; Gong et al., 1998; 
Gripon et al., 2002).  Agarose gel electrophoresis permits fractionation of the different forms of 
HBV DNA, based on size and conformation, resulting in a distinct band migration pattern.  
Southern blot hybridisations are most often performed using radio-labelled probes, however DIG 
probes have been shown to be efficient for the sensitive detection of HBV DNA (Ren and 
Nassal, 2001).  Therefore to eliminate radioactivity exposure, an HBV DIG probe was designed 
that was complementary to the pre-S1 region to detect total HBV DNA.  HepG2.2.15 cell 
cultures and HBV transgenic mice were used to develop this DIG-based Southern blot 
hybridisation technique, subsequently allowing HBV DNA quantification.    
 
3.2.1   HindIII enzymatic digestions enhance HBV fractionation and reduce   
   genomic DNA interference  
 
HBV band migration patterns were improved by HindIII digestion, as shown by the HepG2.2.15 
cell extracts in Figure 3.13.  Three distinct bands were observed corresponding to the rcDNA, 
dsDNA replicative intermediates, and cccDNA.  As the HBV genome does not contain a HindIII 
restriction site, all forms of HBV DNA remain intact, whereas the co-precipitated genomic DNA 
is digested at multiple restriction points.  As cccDNA is covalently closed, it migrates more 
rapidly than the partially double stranded rcDNA, during agarose gel electrophoresis.  The 
rcDNA, dsDNA and cccDNA migrate with equivalent sizes of approximately 4 kilobases (kb), 3.2 
2010 KRISTIE BLOOM 
 
 | CHAPTER  3  –  RESULTS 72 
 
kb and 1.9 kb respectively (Brechot et al., 1981; Gong et al., 1998; Gripon et al., 2002; Ren and 
Nassal, 2001; Sells et al., 1987; Sells et al., 1988; Summers et al., 1990).  As dsDNA 
represents all linear double stranded HBV replicative intermediates present during infection, a 
migration pattern between 3.2 kb and 2 kb is often detected.  HBV single stranded DNA 
(ssDNA) migrates to approximately 1.6 kb, and therefore may co-migrate with cccDNA.  
Although the HBV genome does not contain a HindIII restriction site, it does contain a single 
EcoRI site.  A double digestion, with HindIII and EcoRI, should cleave the HBV genome at the 
single EcoRI restriction site resulting in a distinct 3.2 kb band.  Double digestion of HepG2.2.15 
cells produced three migratory bands, one of which corresponded to the 3.2 kb band expected.  
As a result of this only HindIII enzymatic enhancement of HBV DNA was performed.    
 
Following HindIII digestion, HepG2.2.15 cell samples and HBV transgenic mouse liver samples 
were concentrated to increase the amount of total HBV DNA.  Ethanol precipitation enabled 
significant improvement in HBV DNA detection during Southern blot hybridisation, as shown in 
Figure 3.14.   As a result of the small size of the HBV genome, it is difficult to detect viral DNA 
by Southern blotting, even though there may be numerous copies of the virus within the sample.  
This is evident in the detection limit determined during Southern blot hybridisation, using the 
DIG-labelled HBV DNA probe.  The HBV genome is approximately 3.2 kb in length, therefore a 
single copy of viral DNA is equivalent to approximately 0.4  10-9 ng of DNA.  The minimum 
Southern blot hybridisation limit of detection was found to be 0.019 ng of plasmid DNA.  This 
plasmid concentration corresponds to 5.67  106 copies of HBV DNA.  By concentrating the in 
vitro and in vivo HBV samples, the detection of the different viral DNA species is enhanced, 
which in turn facilitates accurate quantification.  By isolating the cccDNA from other HBV DNA 
species, unambiguous quantification of this replication intermediate should be attainable.    
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Figure 3.13: Southern blot analysis of enzymatic digestions performed on HepG2.2.15 
cell extracts.   Total nucleic acid isolated from HepG2.2.15 cells digested with HindIII migrate 
to form three distinct bands namely rcDNA (A); dsDNA (B); and cccDNA (C), detected by 
chemilumenescence using a DIG-labelled HBV probe.  HBV ssDNA may migrate with cccDNA.  
Double digests of HepG2.2.15 cells, with HindIII and EcoRI, migrate to form three bands where 
(D) represents the 3.2 kb band representing total HBV DNA.  Additional HBV DNA artifacts are 
detected below the 3 kb marker in HindIII/EcoRI digestions.  Controls include standard dilutions 
of pCH9/3091 (positive control) and mouse genomic DNA (negative control). 
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Figure 3.14: Evaluation of HBV samples, prepared from cultured cells and HBV 
transgenic mouse liver, using Southern blot hybridisation. The HepG2.2.15 cells form three 
distinct bands representing the rcDNA, dsDNA and cccDNA/ssDNA.  The HBV transgenic 
mouse liver produces four migratory bands, namely an rcDNA fraction, two dsDNA fractions and 
a cccDNA fraction.  In the HepG2.2.15 cells and the HBV transgenic mouse liver, the largest 
HBV DNA fraction is the dsDNA, indicating HBV replication intermediates.  A pCH-9/3091 
standard dilution was included as a positive control and mouse genomic DNA was included as a 
negative control.   
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3.2.2   Isolation of cccDNA from total HBV using Plasmid-Safe™ ATP-dependent  
   DNase  results in elimination of all DNA species 
 
Both the HBV transgenic mouse liver and HepG2.2.15 cell extractions contain an association of 
rcDNA, dsDNA, ssDNA and cccDNA, as well as co-precipitated genomic DNA.  Since the 
rcDNA is only partially double stranded, the dsDNA is linear, and the genomic DNA nicked, they 
are all susceptible to degradation by specific DNases.  For example, the S1 nuclease cleaves 
single stranded DNA (Wong et al., 2004),  mung bean nuclease degrades single and triple 
stranded DNA (Mazet-Wagner et al., 2006), and Plasmid-Safe™ ATP-dependent DNase 
(Epicentre Biotechnologies) digests linear double stranded DNA and to a lesser extent single 
stranded DNA, however has no effect on circular or supercoiled DNA (Mazet-Wagner et al., 
2006; Singh et al., 2004).  These nucleases have all been used to remove single stranded, 
linear, and rcDNA forms of HBV, as well as degrade sheared genomic DNA, whilst leaving the 
cccDNA intact.  In theory the S1 and mung bean nucleases should cleave the rcDNA and 
sheared genomic DNA, leaving only the cccDNA.  But neither nuclease is able to cleave the 
dsDNA replicative intermediates.  This limits their use to serum samples only, where the rcDNA 
form of HBV predominates and there are no replicative intermediates present.  The Plasmid-
Safe™ ATP-dependent DNase on the other hand, should degrade the dsDNA, genomic DNA 
and the rcDNA leaving only the cccDNA.  This is based on the cccDNA’s covalently closed 
circular DNA form, would be resistant to degradation by this nuclease.  This would be practical 
for cccDNA isolation from both the serum and liver samples.  Therefore to isolate cccDNA, HBV 
transgenic mouse liver samples and HepG2.2.15 cells were incubated with Plasmid-Safe™ 
ATP-dependent DNase.   
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Samples were subsequently analysed by Southern blot, as shown in Figure 3.15.  Three bands 
were detected in the lane containing HepG2.2.15 cells treated with HindIII whilst nothing was 
detected in the lane containing the cccDNA isolation.  A similar result was obtained for the HBV 
transgenic mouse liver samples.  qPCR was additionally used to determine the effects of 
various Plasmid-Safe™ ATP-dependent DNase concentrations on cccDNA found within 
transgenic mouse liver samples.  Figure 3.16 illustrates that cccDNA is not completely protected 
from DNase degradation as expected.  Instead, as enzyme concentrations are increased, 
cccDNA levels decrease.  Untreated HBV transgenic mouse liver samples contain up to 1.05  
106 copies of cccDNA whereas samples treated with 5 U and 10 U of DNase contain an average 
of 2.43  105 and 4.56  104 copies respectively.  This poses a problem as the DNase seems to 
be degrading all forms of the virus DNA, including the cccDNA, making it difficult to quantify 
cccDNA alone. Therefore the Plasmid-Safe™ ATP-dependent DNase treatments were not 
investigated further.    
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Figure 3.15: Isolation of cccDNA from total HBV DNA fractions analysed by Southern blot 
hybridisation.  HindIII digestions of HepG2.2.15 cell extracts and HBV transgenic mouse liver 
results in a typical HBV banding pattern.  No bands were detected in the HepG2.2.15 cell and 
HBV transgenic mouse liver cccDNA extracts.  Plasmid-Safe™ ATP-dependent DNase 
treatments (shown in the cccDNA lanes) digested all HBV fractions, including the cccDNA.  
Positive controls include a 5-fold dilution series of pCH 9/3091, and negative controls include 
mouse genomic DNA.   
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Figure 3.16: cccDNA elimination is proportional to DNase concentration.  HBV transgenic 
mouse DNA extracts were treated with either 5 U or 10 U of Plasmid-Safe™ ATP-dependent 
DNase for 30 minutes and analysed by qPCR.  pTZ-HBVcccR was included as an internal 
control.  The number of cccDNA copies is drastically reduced in the 5 U DNase treated versus 
untreated HBV mouse liver samples.  Increasing DNase concentrations to 10 U further 
diminishes the amount of cccDNA.   Errors bars indicate the SEM where n = 2.   
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3.2.3   HBV DNA migratory patterns correlate to predicted molecular weight  
   configurations   
 
The HBV migration patterns detected using Southern blot hybridisation correspond to previously 
described molecular weights for HindIII digested HBV cccDNA, ssDNA, rcDNA and dsDNA 
(Brechot et al., 1981; Ren and Nassal, 2001; Sells et al., 1988; Summers et al., 1990).  
Although the migratory patterns are determined using molecular weight markers, this is not an 
indication of their actual molecular weights, but instead of their relative DNA conformations.  
The rcDNA migrates within the 5 kb and 4 kb region, which is much slower than the migration of 
the cccDNA.  This is because the rcDNA is an open, double stranded circular form of HBV, as it 
contains an incomplete plus stand and a gap region.  The cccDNA, being covalently closed, 
becomes supercoiled and therefore migrates to approximately 1.9 kb.  The replicative 
intermediates migrate between 3.2 kb and 2 kb as a result of their linear double stranded 
conformation.  The ssDNA migrates to approximately 1.6 kb, just below cccDNA.  Therefore 
although HBV DNA is 3.2 kb in size, the migration of the genome is either hindered or enhanced 
by its conformation.  From these distinct differences in agarose gel molecular weight migration, 
all four forms of HBV DNA can be identified from a single DNA extraction.     
 
To resolve the migratory patterns of HBV DNA, the O’GeneRuler DNA ladder mix, was used as 
a molecular weight marker during gel electrophoresis.  However the ladder had to be excised 
from the gel before alkaline transfer since it interferes with probe hybridisation during Southern 
blot analysis.  This is a result of the high concentration of DNA within the ladder.  As the ladder 
contains such high concentrations of DNA, when compared to the viral DNA concentrations, 
excess probe binds non-specifically to the ladder.  This poses a major problem as the HBV DNA 
bands are not visible during agarose gel electrophoresis, and as a result cannot be assigned a 
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molecular weight. To circumvent this the distance that the molecular weight markers migrated 
during gel electrophoresis was measured, in millimetres, as shown in Figure 3.17a.   Following 
Southern blot hybridisation, the DNA migratory patterns were compared to the gel 
electrophoresis molecular weight marker measurements (Figure 3.17b).  The establishment of 
this molecular weight pattern aided the identification of the HBV rcDNA, cccDNA, ssDNA and 
dsDNA or replication intermediates.   
 
The O’GeneRuler DNA ladder mix spans the 1 kb to 10 kb molecular weight range.  Key 
molecular weight positions, namely 5; 4; 3; 2; 1.5 and 1 kb, were measured based on the 
migration of pCH-9/3091 and the predicted migration pattern of HBV DNA.  The 5-, 4-, and 3 kb 
positions were found to sit at 131 mm, 134 mm, and 139 mm respectively, whilst the 2-, 1.5-, 
and 1 kb positions were located at the 148 mm, 156 mm and 167.5 mm marks respectively. 
Southern blot hybridisation of HBV transgenic mouse liver (Figure 3.17b) indicates that the 
rcDNA is positioned at approximately 4 kb, whilst two dsDNA species are situated between the 
3 kb and 2 kb markers, and finally the cccDNA and ssDNA is located between 2 kb and 1.5 kb.  
It remains difficult to completely isolate cccDNA from ssDNA as a result of their migration 
patterns. This correlates with previous examples of HBV Southern blot migration (Brechot et al., 
1981; Ren and Nassal, 2001) however it is unique in that both rcDNA and cccDNA are detected 
in a single reaction.  This obviates the need for additional enzymatic restriction digestion to 
eliminate cccDNA, or to linearise the HBV DNA.    
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a)          b) 
    
 
 
Figure 3.17: Calculating the relative molecular weight migration patterns of HBV DNA species during Southern blot 
hybridisation.  a) Agarose gel electrophoresis of HBV transgenic mouse liver shows a single smeared pattern with no distinctive 
bands.  The pCH-9/3091 dilution series is not visible.  The ruler is lined up with the O’GeneRuler DNA ladder and shows the distance 
each molecular weight marker moved during electrophoresis.  Measurements for the molecular weight markers are shown.  b) 
Southern blot hybridisation film.  Distinct HBV DNA bands are present in the transgenic mouse liver and pCH-9/3091 samples.  The 
ruler determines the relative positions of the molecular weight markers, allowing the HBV DNA bands to be classified as rcDNA, 
dsDNA, cccDNA and ssDNA.   
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3.2.4   HBV DNA concentrations in HepG2.2.15 cell and HBV transgenic mouse  
   liver extracts                
 
Southern blot hybridisations with DIG-labelled HBV probes were used to determine the 
concentrations of rcDNA, dsDNA and cccDNA within HepG2.2.15 cell samples and media 
supernatants, as well as transgenic mouse liver extracts.  A pCH-9/3091 dilution series was 
included in all hybridisations for precise quantification of HBV DNA.  The HBV band migratory 
patterns for transgenic mouse liver and HepG2.2.15 cells are shown in Figure 3.18.  Southern 
blot film images were analysed using ImageJ software (Abramoff, 2004; Girish and 
Vijayalakshmi, 2004), to determine HBV DNA concentrations.  A pCH-9/3091 standard curve 
was created by determining the integrated density of each DIG-hybridised DNA band and 
plotting it against the plasmid concentration in nanograms (ng).  Integrated density is defined as 
the area multiplied by the mean gray value, where the mean grey value is grey pixilation density 
dependent (Abramoff, 2004).  The area was kept constant throughout analysis, thereby 
measuring only the change in each samples’ mean grey value.  Background noise was 
deducted and the image inverted to improve grey pixel measurements. Total HBV DNA 
concentrations as well as rcDNA to cccDNA ratios were established by determining the 
integrated intensity of rcDNA, dsDNA and cccDNA bands, which were subsequently evaluated 
against the pCH 9/3091 standard curve.  Ethanol concentrations required to efficiently detect 
HBV DNA were taken into account and final quantifications were adjusted accordingly.     
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Figure 3.18: Southern blot hybridisation films of DIG-labelled HBV DNA species.  The migratory patterns of HBV DNA in 
transgenic mouse livers and HepG2.2.15 cell extracts correspond to rcDNA, dsDNA replicative intermediates and cccDNA/ssDNA.  
Chemiluminescent detection is based on 25 µl aliquots of ethanol concentrated and HindIII digested samples.  The pCH9/3091 
standard curve was used to determine the concentration of each HBV DNA species, relative to the integrated density of each band.  
Mouse genomic DNA was included as a negative control.  
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The HBV DNA profiles of transgenic mouse liver and HepG2.2.15 cells were determined by 
chemiluminescent detection, from which the DNA copy number was calculated (Figure 3.19).  
HepG2.2.15 serum samples however, could not be quantified, most likely as a result of viral 
DNA levels below the predetermined detection limit.  Mouse genomic DNA was included as a 
negative control to verify the specificity of the probe and exclude any chemiluminescence 
detection as a result of non-specific binding.  Transgenic mouse liver was found to contain 
slightly more total HBV DNA, with 1.92  106 copies per assay (77 copies per cell), than 
HepG2.2.15 cells with a total of 1.81  106 copies per assay (36 copies per cell).  rcDNA and 
cccDNA profiles were established based on the integrated intensity of individual bands, as a 
result of distinct migration patterns observed by HBV DNA species.  Integrated viral DNA was 
not detected in transgenic mouse livers, most likely as a result of low copy numbers.  The 
proportion of rcDNA to cccDNA was found to be higher in HepG2.2.15 cells, at 1.82 times more 
rcDNA, compared to transgenic mouse liver with only 1.50 times.  Accordingly, transgenic 
mouse liver harbours more cccDNA than HepG2.2.15 cell lines, indicating inherent differences 
between viral replication in these two HBV model systems.  Although HBV DNA was 
successfully quantified using Southern blot hybridisation and chemiluminescence detection, the 
process required sample concentration, restriction endonuclease digestion, and lengthy post-
detection analysis.  This, coupled with high detection limits, restricts the use of hybridisation as 
an efficient method of quantifying HBV viral loads.          
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Figure 3.19: Resolution of HBV DNA profiles by Southern blot hybridisation.   Transgenic 
mouse liver samples contain an average of 7.26  105 copies of cccDNA and 1.09  106 copies 
of rcDNA.  HepG2.2.15 cells retain less cccDNA than transgenic liver with only 6.41  105 
copies, but more rcDNA at 1.17  106 copies.  No HBV was found in mouse genomic DNA.  
Error bars denote the SEM where n = 3.  
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3.3   Validation of the Real-time HBV qPCR assay against the ‘gold   standard’ 
of Southern blot hybridisation 
 
There is a number of qPCR methods available for HBV DNA quantification (Brechtbuehl et al., 
2001; He et al., 2002; Jun-Bin et al., 2003; Singh et al., 2004), yet they fail to substantiate HBV 
detection efficiencies with Southern blot hybridisation.     To determine whether HBV DIG-based 
Southern blot hybridisation and qPCR assay quantify HBV DNA in an equivalent manner, 
identical HepG2.2.15 cell culture extracts and HBV transgenic mouse liver samples analysed by 
Southern blot hybridisation, were evaluated by qPCR.  Most importantly, minimum detection 
limits need to be taken into account as this determines whether occult or low levels of infection 
can be quantified.   By comparing the capacity of these two assays to accurately quantify HBV 
DNA, the most efficient method can be determined.   
 
3.3.1   Detection limits are drastically reduced when using qPCR 
 
HBV transgenic mouse liver, HepG2.2.15 cell extracts and HepG2.2.15 supernatants previously 
analysed and quantified by DIG-based Southern blot hybridisation were evaluated by HBV 
qPCR.  Figure 3.20 shows absolute quantification and HBV DNA profiles of these three samples 
as well as qPCR and Southern blot detection limits.  pTZ-HBVcccR and pCH-9/3091 were 
included as cccDNA and total HBV DNA positive controls (data not shown).  Genomic DNA from 
wild-type mice and water blanks were included as negative controls.  The HBV qPCR assay 
efficiently amplifies cccDNA and total HBV DNA in all three samples, unlike Southern blot 
hybridisation which was unable to detect any viral DNA in HepG2.2.15 supernatants.  The 
qPCR quantification of both HBV DNA species in HepG2.2.15 supernatants is indicative of the 
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low minimum detection limits observed for this assay.  Southern blot hybridisation was unable to 
detect such low copy numbers as a result of its elevated minimum detection limit.   
 
qPCR analysis revealed that transgenic mouse liver retained an average of 2.54  106 copies of 
total HBV DNA (101.6 copies per cell) and 8.65  105 copies of cccDNA (34.6 copies per cell) 
(Figure 3.20), with an HBV DNA ratio of 66% rcDNA to 34% cccDNA.   HepG2.2.15 cell extracts 
contained 1.69  106 copies of total HBV DNA (33.8 copies per cell) and only 8.29  104 copies 
of cccDNA (1.65 copies per cell) whilst HepG2.2.15 supernatants included 1.89  104 copies/µl 
of total HBV DNA and 157 copies/µl of cccDNA (Figure 3.20).  rcDNA therefore remains the 
primary HBV DNA isolate in HepG2.2.15 cell cultures.  These results coincide with the HBV 
DNA profiles observed during absolute quantification of in vitro and in vivo samples (section 
3.1.5), indicating that rcDNA and cccDNA profiles remain relatively consistent in HBV model 
systems.   
 
From this, HBV qPCR has emerged as a more sensitive method for viral DNA detection, 
allowing quantification of very low levels of viral replication.  This may be important in clinical 
analysis of occult infections as well as monitoring drug responses during anti-viral treatments.  
But sensitivity alone does not validate this technique.  HBV quantification results should 
correlate with those obtained during Southern blot hybridisation to justify the accuracy of the 
qPCR assay.        
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Figure 3.20: qPCR quantification of in vitro and in vivo HBV model systems.  HBV 
transgenic mouse livers, HepG2.2.15 cells and HepG2.2.15 supernatants were analysed by 
qPCR.  Transgenic mouse liver and HepG2.2.15 cells maintain high levels of total HBV DNA 
indicating active replication.  Minimum detection limits are shown in red 1.  The low cccDNA and 
total HBV DNA minimum detection limits associated with qPCR allow quantification of HBV DNA 
from HepG2.2.15 supernatants, unlike Southern blot hybridisation.  Mouse genomic DNA was 
included as a negative control.  Error bars indicate the SEM where   n = 3. 
                                               
1
 Note: Southern blot detection limit amended from 5.67  106 to 1.42  106 copies of HBV DNA to 
compensate for adjustments made as a result of ethanol concentrations not performed during qPCR 
analysis.  
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3.3.2   HBV qPCR results are corroborated by Southern blot hybridisation 
 
To validate the HBV qPCR assay, viral DNA quantification was evaluated against Southern blot 
hybridisation from HBV transgenic mouse livers, HepG2.2.15 cell extracts and HepG2.2.15 
supernatants.  Table 3.3 displays paired cccDNA, total HBV DNA and rcDNA results, from both 
techniques.  Values are described as the average number of HBV DNA copies per assay.  Two-
tailed paired Student’s t tests were performed on each data set to establish if variation observed 
between Southern blot hybridisation and qPCR quantification were statistically significant.  HBV 
transgenic mouse livers and HepG2.2.15 cells have corresponding results, showing no 
statistical significance.  As HBV DNA present in HepG2.2.15 supernatants is not detected by 
Southern blotting, the qPCR results are statistically significant.  This statistical significance is 
indicative of the increased sensitivity already observed by qPCR.  Figures 3.21 and 3.22 
graphically represent the results obtained for HBV transgenic mouse livers and HepG2.2.15 cell 
extracts.  The HBV DNA profiles are uniformly distributed between Southern hybridisation and 
qPCR.  cccDNA detection in HepG2.2.15 cell extracts shows the most marked difference 
between these two techniques.  Southern blot hybridisation appears to overestimate the number 
of cccDNA copies.  This may be a result of HBV ssDNA and cccDNA co-migration, as it is 
difficult to distinguish between these two intermediates by Southern blot.  qPCR however, does 
not amplify these intermittent HBV replication intermediates efficiently.  Therefore, as this HBV 
qPCR assay has shown equivalence with the ‘gold standard’ for HBV quantification and displays 
increased sensitivity, it remains a good candidate for monitoring HBV infection, patient’s 
response to therapy and may be used to determine anti-viral efficacies of novel therapeutics.  
Most importantly, cccDNA can be monitored independently of rcDNA, allowing better 
investigation of HBV replication strategies and inhibition associated with RNAi based therapies.                    
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Table 3.3: Quantification of HBV DNA using Southern blot hybridisation and qPCR 
 HBV DNA copies per assay (SEM) p-value 
 Southern Blot Hybridisation HBV qPCR  
cccDNA  
HBV Transgenic Mouse Liver 7.26  105 (2.24  104) 8.65  105 (3.13  105) 0.6825 
HepG2.2.15 Cells 6.41  105 (2.65  105) 8.29  104 (1.19  104) 0.1804 
HepG2.2.15 Supernatant 0 157 (22) 0.0183** 
 Total HBV DNA  
HBV Transgenic Mouse Liver 1.92  106 (2.30  105) 2.54  106 (1.43  105) 0.0513 
HepG2.2.15 Cells 1.81  106 (2.89  104) 1.69  106 (2.39  105) 0.6831 
HepG2.2.15 Supernatant 0 1.89  104 (2.89  103) 0.0224** 
 rcDNA  
HBV Transgenic Mouse Liver 1.09  106 (1.78  105) 1.67  106 (1.93  105) 0.2190 
HepG2.2.15 Cells 1.17  106 (2.72  105) 1.61  106 (2.31  105) 0.0840 
HepG2.2.15 Supernatant 0 1.88  104 (2.87  103) 0.0226** 
 
* mean values (n=3) 
** Statistical significance < 0.05 (5%) 
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Figure 3.21: In vivo validation of HBV qPCR.  Southern blot hybridisation and qPCR 
quantifications correlate across both forms of HBV DNA.  No statistical significance was 
observed between total HBV DNA, cccDNA, or rcDNA quantification.  Both techniques 
established rcDNA as the predominant DNA species in transgenic mouse livers.  The difference 
was only marginal however, as cccDNA was also recovered at high concentrations.  Samples 
were prepared in triplicate and error bars indicate the SEM.      
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Figure 3.22: In vitro validation of HBV qPCR.  Southern blot hybridisation and qPCR show 
equivalent results for total HBV DNA and rcDNA quantification.  cccDNA copy numbers however 
do show variation between the two techniques, however this difference is not statistically 
significant.  Samples were prepared in triplicate and error bars indicate the SEM.     
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3.4  The in vivo efficacy of anti-HBV miRNAs is illustrated by real-time qPCR  
 
Several RNAi-based therapies have been successfully developed to inhibit HBV transcription 
and reduce viral loads (Arbuthnot et al., 2005; Hilleman, 2003).  Anti-HBV knockdown 
efficiencies are predominantly determined by HBsAg ELISAs, DNA of circulating viral particle 
equivalents and relative intrahepatic HBV RNA concentrations.  cccDNA levels however are not 
regularly monitored.  Considering cccDNA drives viral replication and may remain dormant in 
the nucleus of infected hepatocytes, awaiting re-activation, it is important to quantify this form of 
HBV DNA during anti-viral therapy.  Therefore HBV qPCR and RT-PCR was used to establish 
the in vivo RNAi silencing efficiencies of U6 shRNA5 (Carmona et al., 2006), CMV miRNA-122/5 
(Ely et al., 2008), Lin-122/5 and ITR-122/5 (Chattopadhyay et al., 2009).  Plasmid vectors 
expressing HBV replication-competent pgRNA, miRNA shuttles or linear expression cassettes, 
and Renilla luciferase reporter genes were administered by means of hydrodynamic tail vein 
injections.  Mock HBV infections and negative controls were also included.  Serological and 
intrahepatic markers of infection, including total HBV DNA, cccDNA and HBV RNA, were 
analysed relative to reporter gene delivery efficacy or mock HBV infections.        
 
3.4.1   HBV replication is inhibited by RNAi-based therapeutics 
 
Serological HBV DNA quantification was performed on murine serum samples collected at days 
3 and 5 post injection.  A significant decrease in circulating HBV DNA equivalents was observed 
at day 3 in all four RNAi treated isolates when normalised to mock injected mice, as illustrated in 
Figure 3.23.  The U6 shRNA5, CMV miRNA-122/5 and Lin-122/5 cassettes all achieved 95% 
knockdown compared to ITR-122/5 with approximately 90% knockdown.  An increase in viral 
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DNA equivalents was observed 5 days after injection, however U6 shRNA5 and Lin-122/5 
maintained between 85 – 90% knockdown indicating prolonged HBV inhibition.  Mice were 
sacrificed on day 5, allowing quantification of intrahepatic HBV RNA and DNA.  RT-PCR was 
used to quantify total HBV RNA levels relative to the GAPDH housekeeping gene mRNA.  
Declining viral RNA levels were observed in all RNAi treated samples (Figure 3.24).  CMV 
miRNA-122/5 displays the greatest knockdown efficiency at 90%, followed by U6 shRNA5 at 
86%, and finally Lin-122/5 and ITR-122/5 at 81%.  Attenuation of HBV RNA levels as well as the 
serological decline in circulating viral particle equivalents both correlate with effective RNAi-
based silencing of HBV replication.  Furthermore, this indicates that U6 shRNA5, CMV miRNA-
122/5, Lin-122/5 and LTR-122/5 are all capable of inhibiting HBV replication and the subsequent 
release of new viral particles.  However, to determine whether these RNAi-effectors influence 
cccDNA, an intrahepatic HBV DNA profile is required.     
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Figure 3.23: Decline in serum HBV DNA.  Total HBV DNA was quantified at days 3 and 5 post 
injection, relative to the mock.  U6 shRNA5, CMV miRNA-122/5, Lin-122/5 and ITR-122/5 all 
show exceptional inhibition of total HBV DNA after 3 days, however viral loads increase 
somewhat at day 5, most likely as a result of plasmid DNA clearance.  U6 shRNA5 and Lin-
122/5 exhibit the most efficient prolonged HBV inhibition, unlike CMV miRNA-122/5 and ITR-
122/5.  Experiments were performed in triplicate and error bars indicate the SEM.         
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Figure 3.24: Relative quantification of intrahepatic HBV RNA.  RT-PCR was used to 
quantify total HBV RNA relative to the GAPDH mRNA.  Efficient HBV RNA silencing is observed 
by all RNAi effecters indicating HBV transcriptional inactivation.  CMV miRNA-122/5 displayed 
90% knockdown efficiency, whilst U6 shRNA5, Lin-122/5 and ITR-122/5 demonstrated over 
80% knockdown.  Error bars indicate the SEM where n = 3.   
 
 
2010 KRISTIE BLOOM 
 
 | CHAPTER  3  –  RESULTS 97 
 
 
3.4.2   RNAi silencing regulates cccDNA levels  
 
To examine the influence RNAi effecters have on cccDNA, qPCR was used to analyse the HBV 
DNA profiles of murine liver samples collected at day 5.  Mice injected with HBV plasmid DNA 
were used as positive controls whilst mice injected with Renilla luciferase reporter plasmids only 
(psiCHECK2.2) were included as negative controls.  pCH-9/3091 and pTZ-HBVcccR were 
included during qPCR analysis as internal standards.  Intrahepatic total HBV DNA, cccDNA and 
Renilla luciferase were individually quantified by real-time PCR.  Reporter plasmids were 
included during each hydrodynamic injection to control for transgene delivery efficiency.  
Therefore, each sample’s total HBV DNA and cccDNA results were normalised to psiCHECK2.2 
levels.  Figure 3.25 shows the quantification of intrahepatic total HBV DNA and cccDNA, relative 
to Renilla luciferase plasmid delivery.  CMV miRNA-122/5 is the most efficient inhibitor of total 
HBV DNA, with 54% knockdown, however no cccDNA knockdown was detected.  Therefore 
rcDNA synthesis is inhibited, but CMV miRNA-122/5 has no direct influence on established 
cccDNA pools.  Despite the increase in cccDNA, statistically there is no difference between Lin-
122/5 treated samples and the mock.  Lin-122/5 and ITR-122/5 showed poor total HBV DNA 
knockdown, and no inhibition of cccDNA indicating inefficient clearance of intrahepatic viral 
DNA.  U6 shRNA5 demonstrated a total HBV DNA knockdown efficiency of 49%, and an 
unexpected cccDNA knockdown efficiency of 53%.  Consequentially, U6 shRNA5 appears to 
have an inhibitory effect on cccDNA, possibly by preventing the redirection of newly synthesised 
rcDNA to the nucleus.  This in turn would inhibit the development of a nuclear cccDNA pool.       
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Figure 3.25: Quantification of hepatic HBV DNA relative to delivery efficiency.  HBV DNA and the Renilla luciferase reporter 
plasmid were quantified using qPCR.  Total HBV DNA (A) and cccDNA (B) profiles were resolved from murine liver samples 
collected 5 days post-infection.  CMV miRNA-122/5 knocked down total HBV DNA the most efficiently, followed by U6 shRNA5 which 
additionally repressed cccDNA.  Lin-122/5 and ITR-122/5 had no marked effect on total HBV DNA or cccDNA.  Samples were 
analysed in triplicate and error bars indicate the SEM.             
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CHAPTER  4  –  DISCUSSION 
 
4.1.   Efficient real-time HBV qPCR for viral DNA quantification 
 
The ability to accurately detect and quantify serum and intrahepatic HBV DNA has become an 
essential component of chronic HBV management and innovative therapeutic design.  Quick 
and cost-effective techniques, facilitating the rapid detection of viral DNA, are largely required in 
hyper-endemic regions such as Sub-Saharan Africa.  Various commercially available HBsAg 
ELISA and conventional endpoint or competitive PCR-based assays are currently used for the 
clinical diagnosis of acute and chronic HBV infections.  Additionally, these techniques are 
employed to determine anti-HBV drug efficacies, during therapeutic research or patient 
treatment regimens.  However, as described in section 1.1.6, empty viral vesicles interfere with 
the accuracy of the HBsAg ELISA, and conventional PCR requires separate detection and 
quantification platforms.  Real-time qPCR on the other hand, is not influenced by viral antigens, 
and is capable of detecting and quantifying HBV DNA in single reaction.  
 
Absolute quantification of HBV has, more recently, become an important diagnostic tool, 
allowing the sensitive detection of viral DNA from sera and liver biopsies.  Circulating viral 
particles are often used as markers of infection, indicative of either HBV clearance associated 
with acute infections or persistence leading to chronicity.  Brechtbuehl and colleagues 
(Brechtbuehl et al., 2001) have described an efficient Lightcycler™ real-time PCR system with 
SYBR green fluorescence, to detect and quantify the HBV surface gene, allowing total HBV 
DNA quantification.  Although this system permits the sensitive detection of HBV viral loads, it is 
unable to differentiate between rcDNA and cccDNA.   
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Viral mutagenesis, epigenetic regulation and minichromosome formation of cccDNA results in a 
persistent HBV genome (Vivekanandan et al., 2008), that is able to remain dormant during anti-
viral therapy (reviewed by Zoulim, 2004).  Monitoring intrahepatic cccDNA is crucial during drug 
development or chronic HBV management, as viral escape mutants and occult infections will 
readily be detected.  Identifying occult infections is very important in HIV and HBV endemic 
areas, as co-infection increases the risk of developing liver disease (Salmon-Ceron et al., 2005; 
Thio et al., 2002).  The HBV qPCR assay described here is able to accurately quantify total HBV 
DNA as well as differentiate between the two forms of the viral genome, thus providing a 
suitable alternative to current HBV diagnostic tools.  Differential detection of viral DNA species 
is achieved by exploiting the gap region, found only in rcDNA.  Additionally, the cccDNA primers 
were found to not amplify rcDNA non-specifically, as determined by three independent 
experiments, and genomic DNA is not amplified by either primer sets.  Singh and colleagues 
(Singh et al., 2004) have developed a Lightcycler™ based assay that is able to quantify cccDNA 
using fluorescent probes, whilst He (He et al., 2002) and Jun-Bin (Jun-Bin et al., 2003) have 
developed chimaeric primers and FRET based cccDNA detection systems.  A drawback of 
these systems is that they rely on the enzymatic degradation of rcDNA for accurate cccDNA 
quantification.  Furthermore, Southern blot hybridisation was not used to validate the qPCR 
efficiency.   
 
Plasmid-Safe™ ATP-dependent DNase was originally employed to isolate cccDNA from total 
viral DNA.  According to previously described HBV PCR detection and quantification systems 
(Laras et al., 2006; Singh et al., 2004; Wong et al., 2004) enzymatic degradation of partially 
dsDNA and linear DNA, either with Plasmid-Safe™ ATP-dependent DNase or S1 nuclease, is a 
prerequisite for accurate cccDNA quantification.  However during this analysis, DNase 
treatments were found to diminish both in vitro and in vivo cccDNA levels.  Furthermore, in vivo 
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qPCR analysis of increasing enzyme units, indicate cccDNA copy numbers are inversely 
proportional to DNase concentrations.  As a result of this, enzymatic isolation of cccDNA was 
eliminated from further HBV DNA qPCR analysis.  Despite this, cccDNA and total HBV DNA 
primers were found to be sensitive and highly specific for their target sequences.            
 
4.1.1. qPCR minimum detection limits enhance low level HBV DNA quantification      
 
The accuracy and sensitivity of the HBV qPCR assay was successfully validated with Southern 
blot hybridisation.  Although both radioactive and non-radioactive Southern blot analysis has 
been extensively used to quantify total HBV DNA and cccDNA levels (Farza et al., 1988; Gong 
et al., 1998; Gripon et al., 2002; Ren and Nassal, 2001), only limited sensitivity is achieved.  
Distinguishing cccDNA from ssDNA is also problematic, as both migrate to similar positions 
during agarose gel electrophoresis.  Gripon and colleagues (Gripon et al., 2002) as well as 
Gong (Gong et al., 1998) and Summers (Summers et al., 1990) describe cccDNA as the single 
band or smear located just below the 2 kb marker, whilst others (Abdelhamed et al., 2003; Chen 
et al., 2007) describe the same band as only ssDNA.  Here, a single band of approximately 1.9 
kb was observed during Southern blot hybridisation (Figures 3.13 and 3.18) which correlates to 
cccDNA.  However no distinct ssDNA band was observed around 1.5 kb (Figure 3.18), 
suggesting that cccDNA and ssDNA may co-migrate.  This, in turn, explains the overestimation 
of cccDNA observed during Southern blot hybridisation when compared to qPCR analysis.            
 
DIG hybridisation probes displayed poor minimum detection limits when compared to qPCR.  
This was particularly evident during HepG2.2.15 supernatant analysis, where no HBV DNA was 
detected using Southern blot hybridisation; however a distinct HBV DNA profile was obtained 
using qPCR.  The HBV qPCR assay minimum detection limits (10 copies of cccDNA and 84 
copies of total HBV DNA per assay) correspond to other real-time PCR systems (Table 4.1).  
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cccDNA detection sensitivity is in fact, superior to these HBV quantification systems.  This will 
assist with successfully identifying occult infections and determining if novel anti-HBV 
therapeutics are capable of eliminating episomal cccDNA pools.    
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Table 4.1: Sensitivity of HBV real-time qPCR systems  
 HBV DNA copies per assay HBV DNA copies/ml 
 cccDNA Total HBV DNA cccDNA Total HBV DNA 
This study (Bloom 2010) 10  84 2.0  103 1.7   104 
Brechtbuehl et al. (2001) N/A 102 N/A 1.3  104 
Singh et al. (2004) 25 25 - - 
Jun-Bin et al. (2003) 50 N/A - N/A 
He et al. (2002) 100 N/A - N/A 
Wong et al. (2004) 50 50 104 104 
Laras et al. (2006) 100 10 - - 
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4.2.    HBV DNA profiles differ between in vitro and in vivo model systems 
 
HBV in vitro and in vivo model systems, like HepG2.2.15 cell cultures and transgenic mice, are 
often used to determine anti-HBV efficacy when developing new therapeutics.  If a novel 
therapeutic is shown to inhibit HBV replication in vitro, the drug is then assessed in vivo.  HBV 
qPCR was found to be an efficient method of quantifying both cccDNA and total HBV DNA 
levels in both these model systems. Furthermore, the ratio of rcDNA to cccDNA may be 
established.  Although these systems both support active HBV infection, major differences 
between the HBV DNA profiles of HepG2.2.15 cells and transgenic mouse livers was noted.  
One would expect HepG2.2.15 cells to have a similar cccDNA profile to that of transgenic 
mouse liver (40% cccDNA to 60% rcDNA) considering both are hepatocellular in origin.  But, 
95% of HepG2.2.15 cell extracts is rcDNA, which corresponds more with transgenic mouse 
serum and HepG2.2.15 supernatants.  This suggests that the HepG2.2.15 cell line has a very 
high HBV replication rate, which may not mimic natural infection.  In addition, anti-HBV 
therapeutics are likely to have varying effects in these two systems.  Antivirals that inhibit 
reverse transcription of pgRNA to rcDNA may appear to be more efficient in HepG2.2.15 cell 
lines than in transgenic mice, merely as a result of the vast rcDNA pools found in these cell 
lines, however cccDNA may remain unaffected.  This emphasises the need to monitor both 
forms of viral DNA when screening antiviral efficacy.      
 
4.2.1. cccDNA in HBV transgenic mouse model 
 
There are conflicting opinions surrounding the ability of HBV transgenic mice to produce 
cccDNA.  It is generally believed that these mice do not support viral replication through a 
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cccDNA intermediate (Chisari, 1996; Dandri et al., 2005) as pgRNA is instead transcribed 
directly from the integrated HBV genome.  However others have found that HBV transgenic 
mice are able to accommodate small amounts of cccDNA (Guidotti et al., 1995; Raney et al., 
2001).  However in most of these studies, HBV DNA was quantified using Southern blot 
hybridisation where bands corresponding to cccDNA and ssDNA co-migrate and are regarded 
as ssDNA (Chen et al., 2007; Farza et al., 1988).  This is an inaccurate assumption considering 
that both viral DNAs have similar migration profiles.  During this analysis, cccDNA was identified 
in both intrahepatic and serological samples isolated from transgenic mice.  Furthermore, it was 
determined that up to 40% of intrahepatic total HBV DNA is cccDNA.  Southern blot 
hybridisation was found to overestimate cccDNA levels when compared to qPCR as a result of 
HBV linear or ssDNA co-migration.             
 
 
4.3.    RNAi inhibits HBV replication 
 
The in vitro and in vivo silencing of HBV using RNAi based therapies was confirmed with qPCR 
and RT-PCR.  Decreases in circulating viral particles, pgRNA and intrahepatic total HBV DNA 
were established using all four RNAi-effecters.  Silencing of pgRNA halted viral replication which 
resulted in reduced rcDNA levels.  Intrahepatic cccDNA viral pools however remained 
unaffected by CMV miRNA-122/5, Lin-122/5 and ITR-122/5.  U6 shRNA5 however, managed to 
inhibit cccDNA, presumably by inhibiting rcDNA nuclear translocation.  Overall RNAi does not 
appear to destroy established episomal cccDNA, however efficiently inhibits RNA translation 
and therefore reverse transcription and replication of HBV.  This corresponds with results 
reported by Starkey and colleagues (Starkey et al., 2009) who found that anti-HBV shRNAs 
were unable to reduce established cccDNA pools.  Overall, the post-transcriptional silencing of 
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HBV will result in a decline in circulating virions and surface antigen levels, which will give the 
impression of viral clearance.  However this may be misleading, as the cccDNA remains 
unaffected and once therapy ceases, re-infection may occur.  It is therefore critical to monitor 
cccDNA levels when designing new therapeutics to determine their effect on established 
cccDNA pools.    
 
 
4.4.    Conclusion  
  
In summary, the HBV qPCR assay described here is able to detect and quantify rcDNA and 
cccDNA from murine serum and liver samples as well as HepG2.2.15 cell cultures.  Vast 
differences between the HBV DNA profiles of transgenic mouse liver and HepG2.2.15 cell 
extracts was noted.  Specifically, HepG2.2.15 cell cultures produce substantial amounts of 
rcDNA when compared to cccDNA, whilst transgenic mouse liver samples contained a 
significant amount of cccDNA.  As both these model systems are used during anti-HBV effecter 
design, the inherent differences between them may skew the results.  This highlights the 
importance of monitoring the HBV DNA profiles of model systems during therapeutic research.   
    
This qPCR allows the precise monitoring of HBV infection as a result of the capacity for both 
intrahepatic viral DNA and circulating viral particle quantification.  This remains important during 
the clinical evaluation of chronic HBV or HIV/HBV co-infections.  Serum total HBV DNA 
quantification may be used during routine HBV diagnostics. Hepatocellular cccDNA 
quantification may indicate disease progression or response to therapy, although liver biopsies 
remain invasive.  Furthermore, occult infections associated with viral latency and cccDNA 
persistence may readily be quantified using this HBV qPCR assay, as low detection limits give 
rise to increased sensitivity when compared to Southern blot hybridisation.  When compared to 
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other qPCR techniques, this assay provides the most sensitive cccDNA detection platform 
however total HBV DNA detection limits could be improved.  To further decrease minimum 
detection limits and thus increase the sensitivity of the assay, fluorescent hybridisation probes 
could be designed to bind to the gap region or pre-S1 sequence, allowing more accurate 
amplicon detection.  Alternatively, various fluorophores may be linked directly to the primers.  
This would allow multiplexing of total HBV DNA and cccDNA quantification therefore improving 
qPCR efficiency.     
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CHAPTER  5  –  APPENDIX 
 
 
5.1 Vector NTI plasmid maps and sequences 
 
5.1.1   pCH-9/3091 plasmid map  
 
 
pCH-9 3091
6338 bp
Core Protein
Polymerase
X Protein
PreS1
PreS2
Surface
PreCore
PreCore
Ampicillin
CMV Promoter
T3 Promoter
Eco RI (1281)
Pst I (5662)
Sma I (3274)
Xma I (3272)
Nco I (2655)
Nco I (6032)
Apa LI (2862)
Apa LI (3727)
Apa LI (4973)
BamHI (1005)
BamHI (1771)
BamHI (2683)
Ava I (534)
Ava I (1410)
Ava I (2746)
Ava I (3272)
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5.1.2   pHBV 1.3x plasmid map 
 
 
 
pCR-XL-HBV-A1 + BCP + pA
7543 bp
ccdB ORF
Kan
Zeo
HBx ORF
HBx ORF
Surface ORF
PreS2
PreS1
Core ORF
PreC
PreC
Plac
BamHI (2923)
Eco RI (2433)
HindIII (277)
Pst I (2953)
Sma I (6353)
Xma I (6351)
Nco I (587)
Nco I (3807)
Nco I (5822)
Nco I (6261)
Apa LI (794)
Apa LI (4014)
Apa LI (4720)
Apa LI (6608)
Apa LI (7105)
Ava I (678)
Ava I (1653)
Ava I (2562)
Ava I (3898)
Ava I (6341)
Ava I (6351)
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5.1.3   pTZ-HBVcccR M13 sequence  
 
The pTZ-HBVcccR sequence results using M13 forward primers.  The cccDNA forward and 
reverse primers amplify the highlighted target sequence. 
   
ggsgggggtctmtacgactcactatagggaagcttgcatgcaggcctctgcagtcgacgggcccgggatccgattctgccgtaccgt
ccgaccacggggcgcacctctctttacgcggactccccgtctgtgccttctcatctgccggaccgtgtgcacttcgcttcacctccgcac
gtcgcatggagaccaccgtgaacgcccaccaaatattgcccaaggtcttacataagaggactcttggactctcagcaatgtcaacga
ccgacctcgaggcatacttcaaagactgtttgtttaaagactgggaggagttgggggaggagattaggttaaaggtctttgtaccagga
ggctgtaggcataaattggtctgcgcaccagcaccatgcaactttttcacctctgcctaatcatctcttgttcatgtcctactgttcaagcctc
caagctgtgccttgggtggctttggggcatggacattgaccgaattcgaatctagatgcattcgcgaggtaccgagctcgaattcactgg
ccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgta
atagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggaaattgtaagcgttaatattttgttaa
aattc 
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5.2 Laboratory protocols and reagents 
 
5.2.1   Common Reagents 
 
Tris-borate-EDTA (TBE) Buffer 
For a 5  TBE stock solution: 54 g Tris base, 27.5 g boric acid, and 20 mL of 0.5 M EDTA (pH 
8.0) was dissolved in a final volume of 1000 ml.   
 
Tris-acetate-EDTA (TAE) Buffer 
A 50  TAE stock solution was made by dissolving 242 g Tris base in 750 ml of best quality 
water.  To this, 57.1 ml of glacial acetic acid and 100 ml of 0.5 M EDTA (pH 8.0) were added.  
The stock solution was made up to 1000 ml.  For 1   TAE (40 mM Tris acetate, 1 mM EDTA), 
20 ml of 50  TAE stock solution was diluted in 980 ml best quality water.    
 
6  Loading dye 
0.125 g of bromophenol blue was mixed with 30 ml glycerol and 60 ml 10  TBE, to a final 
volume of 100 ml with best quality water (final concentrations: 0.125% bromophenol blue; 30% 
glycerol; 6 TBE) 
 
20  Sodium chloride sodium citrate (SSC) 
A stock solution of 20  SSC was made by mixing 87.7 g Sodium chloride and 44.1 g of Sodium 
citrate with best quality water to a final volume of 500 ml (pH 7.0) 
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5.2.2   Chemically competent cells    
 
A 50 µl aliquot of DH5α E. Coli stock was mixed with 10 ml LB medium (10 g tryptone, 5 g yeast 
extract, 7.5 g sodium chloride to a final volume of 1000ml in best quality water) and was 
incubated gently shaking at 37°C overnight.  Two mi llilitres if this culture was mixed with 40 ml 
fresh LB and incubated for 2 h in a shaking incubator at 37°C, and centrifuged at 600   g for 15 
min.  The supernatant was removed and the bacterial cells re-suspended in 1 ml transformation 
buffer (100 mM calcium chloride, 10 mM PIPES, 15 % glycerol [pH 7.0]) after which an 
additional 19 ml of transformation buffer was added.  The solution was incubated on ice for 30 
min, followed by centrifugation at 200  g for 10 min. The supernatant was decanted and the 
culture re-suspended in 1.5 ml transformation buffer.  Chemically competent cells were stored at 
-70°C.      
 
5.2.3   pTZ-HBV cccR and pTZ-HBVrcR restriction digest analysis 
 
Roche Plasmid DNA extraction Kit 
Bacterial cultures were centrifuged at 2000  g for ten minutes.  The supernatant was removed 
and the pellet was resuspended in 250 µl of suspension buffer with RNase following which 250 
µl of lysis buffer was added to the resuspension and the sample was mixed by gentle inversion.  
The sample was incubated for 5 min at 25°C.  Three hundred and fifty microlitres of chilled 
binding buffer was added to the sample which was mixed gently by inversion. The sample was 
then placed on ice for 5 minutes and centrifuged at 13 000   g.  The supernatant was 
transferred into a high pure filter tube with a collection tube.  The sample was centrifuged at 13 
000  g for 60 s after which the flow through was discarded.  Seven hundred mirolitres of wash 
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buffer II was added to the column and the sample was centrifuged at 13 000  g for 60 s. The 
flowthrough was discarded and the column centrifuged for an additional 60 s at 13 000  g.  
The flowthrough was discarded once again with the collection tube.  The column was placed in 
a 1.5 ml microcentrifuge tube and 100 µl of best quality water was added to the column.  The 
column was centrifuged for 60 s at 13 000  g.  The elution was stored at - 20°C.     
 
EcoRI digestion protocol 
Twenty units of EcoRI enzyme (New England BioLabs, MA, USA) were mixed with 1× NEBuffer 
2 (50 mM NaCl, 10 mM Tris-HCl, 1 mM MgCl2, 1 mM DTT (New England Biolabs)), and 100 ng 
of plasmid DNA (either pTZ-HBVcccR or pTZ-HBVrcR) to a final volume of 15 µl with sterile 
water.  
 
XbaI/BamHI double digestion protocol 
Ten units of XbaI enzyme (New England Biolabs) and 10 U BamHI enzyme (New England 
Biolabs) were mixed with the following: 1× NEBuffer 2 (New England Biolabs), 10× BSA, and 
100 ng of plasmid (either pTZ-HBVcccR or pTZ-HBVrcR) to a final volume of 15 µl. 
 
Gel Electrophoresis 
Ten microlitre aliquots of each digest were mixed with of 6× Loading dye and subjected to 
electrophoresis in a 1.5% agarose gel (1.50 g molecular grade agarose, 100 ml 1× TAE buffer) 
containing 0.0025% Ethidium Bromide.  Electrophoresis was performed for 1 hour at 150V.    
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5.2.4   QIAmp mini tissue protocol 
 
Fifty milligrams of HBV transgenic mouse liver was placed in a 1.5ml microcentrifuge tube and 
150 µl of ATL buffer was added to the sample.  Following this, 20 µl of Proteinase K was added 
to the sample which was mixed by vortexing and incubated at 56°C for 3 hours.  The sample 
was microcentrifuged briefly and then 200 µl of buffer AL was added to the sample.  The mixture 
was pulse vortexed and incubated at 70°C for 10 min utes.   Two hundred and thirty microlitres 
of 100% ethanol was added to the sample and mixed by pulse vortexing.  The sample was then 
transferred to a QIAamp spin column with a collection tube and centrifuged at 6000  g for 1 
min.  The collection tube was replaced and 500 µl of Buffer AW1 was added.  The sample was 
centrifuged at 6000  g for 1 min.  The collection tube was discarded and replaced.  Five 
hundred microlitres of Buffer AW2 was added to the column which was centrifuged at 9 000  g 
for 3 minutes.  The column was placed in a 1.5ml microcentrifuge tube and the collection tube 
discarded.  Two hundred microlitres of best quality water was added to the column and it was 
allowed to stand for 1 min, followed by centrifugation at 6000  g for 1 min.  The sample was 
stored at – 20 °C.      
 
5.2.5   DNA concentration and purity 
 
DNA extracted from transgenic mice, non-transgenic mice, and HepG2.2.15 cells was subjected 
to spectrophotometry in order to determine concentration and purity.  A 1 µl aliquot of each 
extraction was analysed on the NanoDrop® ND-1000 UV-Vis spectrophotometry (NanoDrop 
Technologies) with the NanoDrop ND-1000 3.3 software (Coleman Technologies Inc., Florida, 
USA).  Purity was assessed based on the A260/A280 reading, whilst concentration was 
expressed in the form of nanograms per microlitre.   
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5.2.6   Guanidine single-step RNA isolation 
 
Reagents:  Denaturing Solution (4 M guanidine thiocyanate, 25 mM sodium citrate, 0.5% 
Sarkosyl, 0.1 M 2-mercaptoethanol) 
 2 M Sodium acetate (16.42 g sodium acetate, 35 ml glacial acetic acid and 40 
ml best quality water. Glacial acetic acid was used to adjust the pH to 4.0 
following which the volume was made up to 100 ml with best quality water) 
 Water saturated phenol (100 g phenol crystals were dissolved in best quality 
water at 60°C, following which the upper phase was used for extractions) 
 DEPC-treated water (1 ml Diethyl pyrocarbonate(DEPC) per 1000 ml of best 
quality water.  The solution was incubated at 37°C for 16 h and then autoclaved 
for 20 min at 121°C and 1 kg/cm 2. The DEPC-treated water was left to cool and 
stored at room temperature) 
 
One hundred milligrams of liver tissue was homogenised in 1 ml denaturing solution following 
which 0.1 ml 2M sodium acetate (pH 4) was added and the sample mixed by inversion.  Once 
the solution had thoroughly mixed, 1 ml of water-saturated phenol was then added, followed by 
0.2 ml chloroform.  The solution was mixed thoroughly before incubating for 20 min at 4°C.  The 
sample was then centrifuged for 20 min at 10 000  g for 20 min at 4°C. The upper aqueous 
phase was aliquoted into a new 2 ml microcentrifuge tube and 1 volume of cold, 100% 
isopropanol was added.  The new solution was incubated for 20 min at -20°C followed by 
centrifugation at 10 000  g for 10 min at 4°C.  The supernatant was removed an d 0.3 ml of 
denaturing solution was used to re-suspend the RNA pellet followed by 0.3 ml cold, 100% 
isopropanol.  The sample was incubated at -20°C for  20 min and then centrifuged at 10 000  g 
for 10 min at 4°C.  One millilitre of 75% ethanol w as used to re-suspend the RNA pellet once the 
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supernatant had been discarded.  The sample was incubated at room temperature for 10 min 
and centrifuged for 5 min at 10 000  g (4°C).  The supernatant was removed and the pellet  left 
to air dry following which it was re-suspended in 100 µl DEPC-treated water.  Samples were 
stored at -70°C.        
 
5.2.7  QuantiTect reverse transcription protocol 
 
Additional reagents:  DEPC-treated water (see appendix 5.2.6) 
 
For reverse transcription of RNA to cDNA, all reagents and solutions were prepared and stored 
on ice.  1 µg aliquots of RNA were thawed and mixed with 1 x gDNA Wipeout buffer (Qiagen) to 
a final volume of 14 µl with DEPC-treated water.  Samples were incubated at 42°C for 2 min 
and then returned to ice.  Six microlitres of reverse transcription master mix (1 µl Quantiscript 
Reverse Transcriptase, 4 µl 5  Quantiscript RT Buffer and 1 µl RT Primer Mix) were added to 
the RNA samples which were then mixed gently and incubated at 42°C for 20 minutes.  Finally 
samples were incubated at 95°C for 3 min and then s tored at -20°C until qPCR analysis.      
 
 
5.3 Multiple Alignments 
 
Multiple alignments of three different HBV A1 subtypes from Germany, Uganda and Gambia.   
Regions that correspond completely to one another are shown in yellow whilst highly 
complementary regions are in blue. 
 
                                  1                                               50 
 HBV A1 Uganda (AY934772)     (1) TTCCACAGCTTTCCACCAAGCTCTGCAAGATCCCAGAGTCAGGGGCCTGT 
 HBV A1 Gambia (AY934764)     (1) TTCCACAGCTTTCCACCAAGCTCTGCAAGATCCCAGAGTCAGGGGCCTGT 
HBV A1 Germany (AY738139)     (1) TTCCACTGCCTTCCACCAAGCTCTGCAGGATCCCAGAGTCAGGGGTCTGT 
                Consensus     (1) TTCCACAGCTTTCCACCAAGCTCTGCAAGATCCCAGAGTCAGGGGCCTGT 
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                                  51                                             100 
 HBV A1 Uganda (AY934772)    (51) ATCTTCCTGCTGGTGGCTCCAGTTCAGGAACACTCAACCCTGTTCCAAAT 
 HBV A1 Gambia (AY934764)    (51) ATTTTCCTGCTGGTGGCTCCAGTTCAGGAATAGTAAACCCTGTTCCGAAT 
HBV A1 Germany (AY738139)    (51) ATTTTCCTGCTGGTGGCTCCAGTTCAGGAACAGTAAACCCTGCTCCGAAT 
                Consensus    (51) ATTTTCCTGCTGGTGGCTCCAGTTCAGGAACAGTAAACCCTGTTCCGAAT 
                                  101                                            150 
 HBV A1 Uganda (AY934772)   (101) ATTGCCTCTCACATCTCGTCAATCTCCTCGAGGACTGGGGACCCTGCGTC 
 HBV A1 Gambia (AY934764)   (101) ATTGCCTCTCACATCTCGTCAATCTCCTCGAGGACTGGGGACCCTGCACC 
HBV A1 Germany (AY738139)   (101) ATTGCCTCTCACATCTCGTCAATCTCCGCGAGGACTGGGGACCCTGTGAC 
                Consensus   (101) ATTGCCTCTCACATCTCGTCAATCTCCTCGAGGACTGGGGACCCTGCG C 
                                  151                                            200 
 HBV A1 Uganda (AY934772)   (151) GAACATGGAGAACATCACATCAGGATTCCTAGGACCCCTGCTCGTGTTAC 
 HBV A1 Gambia (AY934764)   (151) GACCATGGAGAACATCACATCAGGATTCCTAGGACCCCTGCTCGTGTTAC 
HBV A1 Germany (AY738139)   (151) GAACATGGAGAACATCACATTAGGATTCCTAGGACCCCTGCTCGTGTTAC 
                Consensus   (151) GAACATGGAGAACATCACATCAGGATTCCTAGGACCCCTGCTCGTGTTAC 
                                  201                                            250 
 HBV A1 Uganda (AY934772)   (201) AGGCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACCGCAGAGTCTA 
 HBV A1 Gambia (AY934764)   (201) AGGCGGGGTTTTTCTTGTTGACAAAAATCCTCACAATACCGCAGAGTCTA 
HBV A1 Germany (AY738139)   (201) AGGCGGTGTTTTTCTTGTTGACAAGAATCCTCACAATACCACAGAGTCTA 
                Consensus   (201) AGGCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACCGCAGAGTCTA 
                                  251                                            300 
 HBV A1 Uganda (AY934772)   (251) GACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGCCCACCCGTGTGTCT 
 HBV A1 Gambia (AY934764)   (251) GACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGATCACCCGTGTGTCT 
HBV A1 Germany (AY738139)   (251) GACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGATCACCCGTGTGTCT 
                Consensus   (251) GACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGATCACCCGTGTGTCT 
                                  301                                            350 
 HBV A1 Uganda (AY934772)   (301) TGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCCTGTC 
 HBV A1 Gambia (AY934764)   (301) TGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCCTGTC 
HBV A1 Germany (AY738139)   (301) TGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCCTGTC 
                Consensus   (301) TGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCCTGTC 
                                  351                                            400 
 HBV A1 Uganda (AY934772)   (351) CTCCAATTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTTTTATCATA 
 HBV A1 Gambia (AY934764)   (351) CTCCAATTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTTTTATCATA 
HBV A1 Germany (AY738139)   (351) CTCCAATTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTTTTATCATA 
                Consensus   (351) CTCCAATTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTTTTATCATA 
                                  401                                            450 
 HBV A1 Uganda (AY934772)   (401) TTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTATTGGTTCTTCTGGA 
 HBV A1 Gambia (AY934764)   (401) TTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTATTGGTTCTTCTGGA 
HBV A1 Germany (AY738139)   (401) TTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTATTGGTTCTTCTGGA 
                Consensus   (401) TTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTATTGGTTCTTCTGGA 
                                  451                                            500 
 HBV A1 Uganda (AY934772)   (451) TTATCAAGGTATGTTGCCCGTTTGTCCTCTGATTCCAGGATCCACAACAA 
 HBV A1 Gambia (AY934764)   (451) TTGTCAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCACAACAA 
HBV A1 Germany (AY738139)   (451) TTATCAAGGTATGTTGGCCGTTTGTCCTCTAATTCCAGGATCAACAACAA 
                Consensus   (451) TTATCAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCACAACAA 
                                  501                                            550 
 HBV A1 Uganda (AY934772)   (501) CCAGTACGGGACCCTGCAGAACCTGCACGACTCCTGCTCAAGGCAACTCT 
 HBV A1 Gambia (AY934764)   (501) CCAGCACGGGACCCTGCAGAACCTGCACGACTCCTGCTCAAGGCAACTCT 
HBV A1 Germany (AY738139)   (501) CCAGTACGGGACCATGCAAAACCTGCACGACTCCTGCTCAAGGCAACTCT 
                Consensus   (501) CCAGTACGGGACCCTGCAGAACCTGCACGACTCCTGCTCAAGGCAACTCT 
                                  551                                            600 
 HBV A1 Uganda (AY934772)   (551) ATGTTTCCCTCATGTTGCTGTACAAAACCTACGGATGGAAATTGCACCTG 
 HBV A1 Gambia (AY934764)   (551) ATGTTTCCCTCATGTTGTTGTACAAAACCTACGGACGGAAATTGCACCTG 
HBV A1 Germany (AY738139)   (551) ATGTTTCCCTCATGTTGCTGTACAAAACCTACGGATGGAAATTGCACCTG 
                Consensus   (551) ATGTTTCCCTCATGTTGCTGTACAAAACCTACGGATGGAAATTGCACCTG 
                                  601                                            650 
 HBV A1 Uganda (AY934772)   (601) TATTCCCATCCCATCATCTTGGGCTTTCGTAAAATACCTATGGGAGTGGG 
 HBV A1 Gambia (AY934764)   (601) TATTCCCATCCCATCATCATGGGCTTTCGCAAAATACCTATGGGAGTGGG 
HBV A1 Germany (AY738139)   (601) TATTCCCATCCCATCGTCCTGGGCTTTCGCAAAATACCTATGGGAGTTGG 
                Consensus   (601) TATTCCCATCCCATCATC TGGGCTTTCGCAAAATACCTATGGGAGTGGG 
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                                  651                                            700 
 HBV A1 Uganda (AY934772)   (651) CCTCAGTCCGTTTCTCTTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGG 
 HBV A1 Gambia (AY934764)   (651) CCTCAGTCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGG 
HBV A1 Germany (AY738139)   (651) CCTCAGTCCGTTTCTCTTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGG 
                Consensus   (651) CCTCAGTCCGTTTCTCTTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGG 
                                  701                                            750 
 HBV A1 Uganda (AY934772)   (701) TTCGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTG 
 HBV A1 Gambia (AY934764)   (701) TTCGTATGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTG 
HBV A1 Germany (AY738139)   (701) TTCGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGCTATATGGATGATGTG 
                Consensus   (701) TTCGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTG 
                                  751                                            800 
 HBV A1 Uganda (AY934772)   (751) GTTTTGGGGGCCAAGTCTGTACAACATCTTGAGTCCCTTTATACCGCTGT 
 HBV A1 Gambia (AY934764)   (751) GTATTGGGGGCCAAGTCTGTACAACATCTTGAGTCCCTTTATACCGCTGT 
HBV A1 Germany (AY738139)   (751) GTATTGGGGGCCAAGTCTGTACAGCATCGTGAGTCCCTTTATACCGCTGT 
                Consensus   (751) GTATTGGGGGCCAAGTCTGTACAACATCTTGAGTCCCTTTATACCGCTGT 
                                  801                                            850 
 HBV A1 Uganda (AY934772)   (801) TACCAATTTTCTTTTGTCTTTGGGTATACATTTAAACCCTAACAAAACAA 
 HBV A1 Gambia (AY934764)   (801) TACCAATTTTCTTTTGTCTTTGGGTATACATCTAAACCCTAACAAAACAA 
HBV A1 Germany (AY738139)   (801) TACTAATTTTCTTTTGTCTCTGGGTATACATTTAAACCCTAACAAAACAA 
                Consensus   (801) TACCAATTTTCTTTTGTCTTTGGGTATACATTTAAACCCTAACAAAACAA 
                                  851                                            900 
 HBV A1 Uganda (AY934772)   (851) AGAGATGGGGTTATTCCCTAAACTTCATGGGATATGTAATTGGAAGTTGG 
 HBV A1 Gambia (AY934764)   (851) AAAGATGGGGTTATTCCCTAAACTTCATGGGTTACATAATTGGAAGTTGG 
HBV A1 Germany (AY738139)   (851) GAAGATGGGGTTATTCCCTAAACTTCATGGGTTACATAATTGGAAGTTGG 
                Consensus   (851) AAAGATGGGGTTATTCCCTAAACTTCATGGGTTACATAATTGGAAGTTGG 
                                  901                                            950 
 HBV A1 Uganda (AY934772)   (901) GGTACATTGCCACAGGATCATATTATACAAAAAATCAAACACTGTTTTAG 
 HBV A1 Gambia (AY934764)   (901) GGATCATTGCCACAGGATCATATTGTACAAAAAATCAAAAATTGTTTTAG 
HBV A1 Germany (AY738139)   (901) GGAACTTTGCCACAGGATCATATTGTGCAAAAGATCAAACACTGTTTTAG 
                Consensus   (901) GGAACATTGCCACAGGATCATATTGTACAAAAAATCAAACACTGTTTTAG 
                                  951                                           1000 
 HBV A1 Uganda (AY934772)   (951) AAAACTTCCTCTCAATCGACCTATTGATTGGAAAGTATGTCAACGAATTG 
 HBV A1 Gambia (AY934764)   (951) AAAACTTCCTATTAATAGGCCTATTGATTGGAAAGTATGTCAAAGAATTG 
HBV A1 Germany (AY738139)   (951) AAAACTTCCTGTTAACAGGCCTATTGATTGGAAAGTATGTCAAAGAATTG 
                Consensus   (951) AAAACTTCCT TTAATAGGCCTATTGATTGGAAAGTATGTCAAAGAATTG 
                                  1001                                          1050 
 HBV A1 Uganda (AY934772)  (1001) TGGGTCTTTTGGGCTTTGCCGCTCCATTTACACAATGTGGTTACCCGGCC 
 HBV A1 Gambia (AY934764)  (1001) TGGGTCTGTTGGGCTTTGCAGCTCCCTTTACACAATGTGGATACCCTGCC 
HBV A1 Germany (AY738139)  (1001) TGGGTCTTTTGGGCTTTGCTGCTCCATTTACACAATGTGGATATCCTGCC 
                Consensus  (1001) TGGGTCTTTTGGGCTTTGC GCTCCATTTACACAATGTGGATACCCTGCC 
                                  1051                                          1100 
 HBV A1 Uganda (AY934772)  (1051) TTAATGCCCTTGTATGCATGTATACAGGCGAAACAGGCTTTTACTTTCTC 
 HBV A1 Gambia (AY934764)  (1051) TTAATGCCTTTGTATGCGTGTATACAAGCTAAACAGGCTTTTACTTTCTC 
HBV A1 Germany (AY738139)  (1051) TTAATGCCTTTGTATGCATGTATACAAGCTAAACAGGCTTTCACTTTCTC 
                Consensus  (1051) TTAATGCCTTTGTATGCATGTATACAAGCTAAACAGGCTTTTACTTTCTC 
                                  1101                                          1150 
 HBV A1 Uganda (AY934772)  (1101) GCCAACTTACAAGGCCTTTCTAAGTAAACAGTATATGAACCTTTACCCCG 
 HBV A1 Gambia (AY934764)  (1101) GCCAACTTACAAGGCCTTTCTAAGTAAACAGTATGTGAACCTTTACCCCG 
HBV A1 Germany (AY738139)  (1101) GCCAACTTACAAGGCCTTTCTAAGTAAACAGTACATGAACCTTTACCCCG 
                Consensus  (1101) GCCAACTTACAAGGCCTTTCTAAGTAAACAGTATATGAACCTTTACCCCG 
                                  1151                                          1200 
 HBV A1 Uganda (AY934772)  (1151) TTGCGCGGCAACGGCCTGGTCTATGCCAAGTGTTTGCTGACGCAACCCCC 
 HBV A1 Gambia (AY934764)  (1151) TTGCCCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCC 
HBV A1 Germany (AY738139)  (1151) TTGCTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCC 
                Consensus  (1151) TTGC CGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCC 
                                  1201                                          1250 
 HBV A1 Uganda (AY934772)  (1201) ACTGGCTGGGGCTTGGCTATTGGCCATCAGCGCATGCGTGGAACCTTTGT 
 HBV A1 Gambia (AY934764)  (1201) ACTGGGTGGGGCTTGGCCATTGGCCATCAGCGCATGCGCGGAACCTTTGT 
HBV A1 Germany (AY738139)  (1201) ACTGGCTGGGGCTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGT 
                Consensus  (1201) ACTGGCTGGGGCTTGGCCATTGGCCATCAGCGCATGCGTGGAACCTTTGT 
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                                  1251                                          1300 
 HBV A1 Uganda (AY934772)  (1251) GGCTCCTCTGCCGATCCATACTGCGGAACTCCTAGCYGCCTGTTTTGCTC 
 HBV A1 Gambia (AY934764)  (1251) GGCTCCTCTGCCGATCCATACTGCGGAACTCCTAGCAGCTTGTTTTGCTC 
HBV A1 Germany (AY738139)  (1251) GGCTCCTCTGCCGATCCATACTGCGGAACTCCTAGCCGCTTGTTTTGCTC 
                Consensus  (1251) GGCTCCTCTGCCGATCCATACTGCGGAACTCCTAGC GCTTGTTTTGCTC 
                                  1301                                          1350 
 HBV A1 Uganda (AY934772)  (1301) GCAGCCGGTCTGGAGCAAAMCTCATCGGGACTGATAATTCTGTCGTCCTC 
 HBV A1 Gambia (AY934764)  (1301) GCAGCCGGTCTGGAGCAAAACTCATTGGGACTGATAATTCTGTCGTCCTC 
HBV A1 Germany (AY738139)  (1301) GCAGCCGGTCTGGAGCAAAGCTCATCGGAACTGACAATTCTGTCGTCCTC 
                Consensus  (1301) GCAGCCGGTCTGGAGCAAA CTCATCGGGACTGATAATTCTGTCGTCCTC 
                                  1351                                          1400 
 HBV A1 Uganda (AY934772)  (1351) TCGCGGAAATATACATCGTTTCCATGGCTGCTAGGGTGTACTGCCAACTG 
 HBV A1 Gambia (AY934764)  (1351) TCTCGGAAATATACCTCCTTTCCATGGCTGCTAGGCTGTACTGCCAACTG 
HBV A1 Germany (AY738139)  (1351) TCGCGGAAATATACATCGTTTCCATGGCTGCTAGGCTGTGCTGCCAACTG 
                Consensus  (1351) TCGCGGAAATATACATCGTTTCCATGGCTGCTAGGCTGTACTGCCAACTG 
                                  1401                                          1450 
 HBV A1 Uganda (AY934772)  (1401) GATTCTTCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAATCCCG 
 HBV A1 Gambia (AY934764)  (1401) GATTCTTCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAATCCCG 
HBV A1 Germany (AY738139)  (1401) GATCCTTCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAATCCCG 
                Consensus  (1401) GATTCTTCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAATCCCG 
                                  1451                                          1500 
 HBV A1 Uganda (AY934772)  (1451) CGGACGACCCCTCACGGGGCCGCTTGGGTCTCTATCGTCCCCTTCTCCGT 
 HBV A1 Gambia (AY934764)  (1451) CGGACGACCCCTCTCGGGGCCGCTTGGGACTCTATCGTCCCCTTCTCCGT 
HBV A1 Germany (AY738139)  (1451) CGGACGACCCCTCTCGGGGCCGCTTGGGACTCTCTCGTCCCCTTCTCCGT 
                Consensus  (1451) CGGACGACCCCTCTCGGGGCCGCTTGGGACTCTATCGTCCCCTTCTCCGT 
                                  1501                                          1550 
 HBV A1 Uganda (AY934772)  (1501) CTGCCGTACCGTCCGACCACGGGGCGCACCTCTCTTTACGCGGTCTCCCC 
 HBV A1 Gambia (AY934764)  (1501) CTGCCGTACCGACCGACCACGGGGCGCACCTCTCTTTACGCGGTCTCCCC 
HBV A1 Germany (AY738139)  (1501) CTGCCGTTCCAGCCGACCACGGGGCGCACCTCTCTTTACGCGGTCTCCCC 
                Consensus  (1501) CTGCCGTACCG CCGACCACGGGGCGCACCTCTCTTTACGCGGTCTCCCC 
                                  1551                                          1600 
 HBV A1 Uganda (AY934772)  (1551) GTCTGTGCCTTCTCATCTGCCGGTCCGTGTGCACTTCGCTTCACCTCTGC 
 HBV A1 Gambia (AY934764)  (1551) GTCTGTGCCTTCTCATCTGCCGGACCGTGTGCACTTCGCTTCACCTCTGC 
HBV A1 Germany (AY738139)  (1551) GTCTGTGCCTTCTCATCTGCCGGTCCGTGTGCACTTCGCTTCACCTCTGC 
                Consensus  (1551) GTCTGTGCCTTCTCATCTGCCGGTCCGTGTGCACTTCGCTTCACCTCTGC 
                                  1601                                          1650 
 HBV A1 Uganda (AY934772)  (1601) ACGTTGCATGGAGACCACCGTGAACGCCCATCAGATCCTGCCCAAGGTCT 
 HBV A1 Gambia (AY934764)  (1601) ACGTTGCATGGAGACCACCGTGAACGCCCATCAGATCCTGCCCAAGGTCT 
HBV A1 Germany (AY738139)  (1601) ACGTTGCGTGGAGACCACCGTGAACGCCCATCAGATCCTGCCCAAGGTCT 
                Consensus  (1601) ACGTTGCATGGAGACCACCGTGAACGCCCATCAGATCCTGCCCAAGGTCT 
                                  1651                                          1700 
 HBV A1 Uganda (AY934772)  (1651) TACATAAGAGGACTCTTGGACTCCCAGCAATGTCAACGACCGACCTTGAG 
 HBV A1 Gambia (AY934764)  (1651) TACATAAGCGGACTCTTGGACTCCCAGCAATGTCAACGACCGACCTTGAG 
HBV A1 Germany (AY738139)  (1651) TACATAAGAGGACTCTTGGACTCCCAGCAATGTCAACGACCGACCTTGAG 
                Consensus  (1651) TACATAAGAGGACTCTTGGACTCCCAGCAATGTCAACGACCGACCTTGAG 
                                  1701                                          1750 
 HBV A1 Uganda (AY934772)  (1701) GCCTACTTCAAAGACTGTGTGTATAAAGACTGGGAGGTGTTGGGGGAGGA 
 HBV A1 Gambia (AY934764)  (1701) GCCTACTTCAAAGACTGTGTGTTTAAAGACTGGGAGGAGTTGGGGGAGGA 
HBV A1 Germany (AY738139)  (1701) GCCTACTTCAAAGACTGTGTGTTTAAGGACTGGGAGGAGCTGGGGGAGGA 
                Consensus  (1701) GCCTACTTCAAAGACTGTGTGTTTAAAGACTGGGAGGAGTTGGGGGAGGA 
                                  1751                                          1800 
 HBV A1 Uganda (AY934772)  (1751) GATTAGGTTAATGATCTGTGTATTAGGAGGCTGTAGGCATAAATTGGTCT 
 HBV A1 Gambia (AY934764)  (1751) GATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCT 
HBV A1 Germany (AY738139)  (1751) GATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCT 
                Consensus  (1751) GATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCT 
                                  1801                                          1850 
 HBV A1 Uganda (AY934772)  (1801) GCGCACCAGCACCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTA 
 HBV A1 Gambia (AY934764)  (1801) GCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTA 
HBV A1 Germany (AY738139)  (1801) GCGCACCAGCACCAYGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTA 
                Consensus  (1801) GCGCACCAGCACCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTA 
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                                  1851                                          1900 
 HBV A1 Uganda (AY934772)  (1851) CATGTCCCACTGTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC 
 HBV A1 Gambia (AY934764)  (1851) CATGTCCCACTCTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGC 
HBV A1 Germany (AY738139)  (1851) CATGTCCCACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGC 
                Consensus  (1851) CATGTCCCACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGC 
                                  1901                                          1950 
 HBV A1 Uganda (AY934772)  (1901) ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTC 
 HBV A1 Gambia (AY934764)  (1901) ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTC 
HBV A1 Germany (AY738139)  (1901) ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTC 
                Consensus  (1901) ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTC 
                                  1951                                          2000 
 HBV A1 Uganda (AY934772)  (1951) TTTTTTGCCTTCTGACTTCTTTCCTTCAGTCCGGGATCTACTTGATACAG 
 HBV A1 Gambia (AY934764)  (1951) GTTTTTGCCTTCTGACTTCTTTCCTTCCGTCCGAGATCTCCTAGATACCG 
HBV A1 Germany (AY738139)  (1951) GTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTCCTAGACACCG 
                Consensus  (1951) GTTTTTGCCTTCTGACTTCTTTCCTTCCGTCCGAGATCTCCTAGATACCG 
                                  2001                                          2050 
 HBV A1 Uganda (AY934772)  (2001) CCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCATTGCTCACCT 
 HBV A1 Gambia (AY934764)  (2001) CCTCAGCTCTGTACCGGGAAGCATTAGAGTCTCCTGAGCATTGCTCACCT 
HBV A1 Germany (AY738139)  (2001) CCTCAGCTCTGTATCGAGAAGCCTTAGAGTCTCCTGAGCATTGCTCACCT 
                Consensus  (2001) CCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCATTGCTCACCT 
                                  2051                                          2100 
 HBV A1 Uganda (AY934772)  (2051) CACCATACAGCACTCAGGCAAGCCATTCTCTGCTGGGTGGAATTAATGAC 
 HBV A1 Gambia (AY934764)  (2051) CACCACACAGCACTAAGGCAAGCCATTCTTTGTTGGGGGGAATTAATGAC 
HBV A1 Germany (AY738139)  (2051) CACCATACTGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAATTGATGAC 
                Consensus  (2051) CACCATACAGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAATTAATGAC 
                                  2101                                          2150 
 HBV A1 Uganda (AY934772)  (2101) TCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCATCCAGGGATC 
 HBV A1 Gambia (AY934764)  (2101) TCTAGCTACCTGGGTGGGCAATAATTTGGAAGATCCAGCATCCAGGGATC 
HBV A1 Germany (AY738139)  (2101) TCTAGCTACCTGGGTGGGTAATAATTTGCAAGATCCAGCATCCAGGGATC 
                Consensus  (2101) TCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCATCCAGGGATC 
                                  2151                                          2200 
 HBV A1 Uganda (AY934772)  (2151) TAGTAGTCAATTATGTTAATACTAACATGGGCCTAAAGATCAGACAACTA 
 HBV A1 Gambia (AY934764)  (2151) TAGTAGTCAATTATGTTAATACTAACATGGGCCTAAAGATCAGGCAACTA 
HBV A1 Germany (AY738139)  (2151) TAGTAGTCAATTATGTTAATACTAACATGGGTTTAAAAATCAGGCAACTA 
                Consensus  (2151) TAGTAGTCAATTATGTTAATACTAACATGGGCCTAAAGATCAGGCAACTA 
                                  2201                                          2250 
 HBV A1 Uganda (AY934772)  (2201) TTGTGGTTTCATATTTCTTGCCTTACTTTTGGAAGAGAAACTGTCCTTGA 
 HBV A1 Gambia (AY934764)  (2201) TTGTGGTTTCATATTTCCTGCCTTACTTTTGGAAGAGAAACTGTACTTGA 
HBV A1 Germany (AY738139)  (2201) TTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGAGAGACGGTACTTGA 
                Consensus  (2201) TTGTGGTTTCATATTTCTTGCCTTACTTTTGGAAGAGAAACTGTACTTGA 
                                  2251                                          2300 
 HBV A1 Uganda (AY934772)  (2251) GTATTTGGTCTCCTTCGGAGTGTGGATTCGCACTCCTCCAGCCTATAGAC 
 HBV A1 Gambia (AY934764)  (2251) GTATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCTCCAGCTTATCGAC 
HBV A1 Germany (AY738139)  (2251) ATATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCTCCAGCCTATAGAC 
                Consensus  (2251) GTATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCTCCAGCCTATAGAC 
                                  2301                                          2350 
 HBV A1 Uganda (AY934772)  (2301) CACCAAATGCCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGA 
 HBV A1 Gambia (AY934764)  (2301) CACCAAATGCCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGA 
HBV A1 Germany (AY738139)  (2301) CACCAAATGCCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGA 
                Consensus  (2301) CACCAAATGCCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGA 
                                  2351                                          2400 
 HBV A1 Uganda (AY934772)  (2351) CGACGAGACCGAGGTAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG 
 HBV A1 Gambia (AY934764)  (2351) CGACGGGACCGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG 
HBV A1 Germany (AY738139)  (2351) CGACGGGACCGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG 
                Consensus  (2351) CGACGGGACCGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG 
                                  2401                                          2450 
 HBV A1 Uganda (AY934772)  (2401) ACGAAGATCTCAATCGCCGCGTCGCAGAAGATCTCAATCTCGGGAATCTC 
 HBV A1 Gambia (AY934764)  (2401) ACGAAGATCTCAATCGCCGCGTCGCAGAAGATCTCAATCTCGGGAATCTC 
HBV A1 Germany (AY738139)  (2401) ACGCAGATCTCAATCGCCGCGTCGCAGAAGATCTCAATCTCGGGAATCTC 
                Consensus  (2401) ACGAAGATCTCAATCGCCGCGTCGCAGAAGATCTCAATCTCGGGAATCTC 
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                                  2451                                          2500 
 HBV A1 Uganda (AY934772)  (2451) AATGTTAGTATTCCTTGGACTCATAAGGTGGGAAATTTTACTGGGCTTTA 
 HBV A1 Gambia (AY934764)  (2451) AATGTTAGTATTCCTTGGACACATAAGGTGGGAAATTTTACTGGGCTTTA 
HBV A1 Germany (AY738139)  (2451) AATGTTAGTATTCCTTGGACTCATAAGGTGGGAAACTTTACGGGGCTTTA 
                Consensus  (2451) AATGTTAGTATTCCTTGGACTCATAAGGTGGGAAATTTTACTGGGCTTTA 
                                  2501                                          2550 
 HBV A1 Uganda (AY934772)  (2501) TTCCTCTACTGTCCCTATCTTTAATCCTGAATGGCAAACTCCTTCCTTTC 
 HBV A1 Gambia (AY934764)  (2501) TTCCTCTACTGTACCCATCTTTAATCCTGAATGGCAAACTCCTACTTTTC 
HBV A1 Germany (AY738139)  (2501) TTCCTCTACAGTACCTATCTTCAATCCTGAATGGCAAACTCCTTCCTTCC 
                Consensus  (2501) TTCCTCTACTGTACCTATCTTTAATCCTGAATGGCAAACTCCTTCCTTTC 
                                  2551                                          2600 
 HBV A1 Uganda (AY934772)  (2551) CTAAAATCCATTTACATGAGGACATTATTAATAGGTGTCAGCAATTTGTG 
 HBV A1 Gambia (AY934764)  (2551) CCAAGATTCATTTACATGAGGACATTGTTAATAGGTGTCAACAATTTGTG 
HBV A1 Germany (AY738139)  (2551) CTAAGATTCATTTACAAGAGGACATTATTAATAGGTGTCAACAATTTGTG 
                Consensus  (2551) CTAAGATTCATTTACATGAGGACATTATTAATAGGTGTCAACAATTTGTG 
                                  2601                                          2650 
 HBV A1 Uganda (AY934772)  (2601) GGTCCTCTCACTGTAAATGAAAAGAGAAGATTGAAATTAATTATGCCTGC 
 HBV A1 Gambia (AY934764)  (2601) GGTCCTCTCACAGTAAATGAAAAAAGAAGATTAAAATTGATTATGCCTGC 
HBV A1 Germany (AY738139)  (2601) GGCTCTCTCACTGTAAATGAAAAAAGAAGATTGAAATTAATTATGCCTGC 
                Consensus  (2601) GGTCCTCTCACTGTAAATGAAAAAAGAAGATTGAAATTAATTATGCCTGC 
                                  2651                                          2700 
 HBV A1 Uganda (AY934772)  (2651) TAGATTTTTTCCTAACAGCACCAAATATTTGCCTCTAGACAAAGGGATTA 
 HBV A1 Gambia (AY934764)  (2651) TAGATTCTATCCTAACAGTACGAAATATTTGCCCCTAGACAAAGGAATTA 
HBV A1 Germany (AY738139)  (2651) TAGATTCTATCCTACTCACACTAAATATTTGCCCTTAGACAAAGGAATTA 
                Consensus  (2651) TAGATTCTATCCTAACAGCAC AAATATTTGCCCCTAGACAAAGGAATTA 
                                  2701                                          2750 
 HBV A1 Uganda (AY934772)  (2701) AACCTTATTATCCTGATCAAGTAGTTAATCATTACTTCCAGACCCGACAT 
 HBV A1 Gambia (AY934764)  (2701) AACCTTATTATCCTGATCATGTAGTTAATCATTACTTCCAGACCCGACAT 
HBV A1 Germany (AY738139)  (2701) AACCTTATTATCCAGATCAGGTAGTTAATCATTACTTCCAAACCAGACAT 
                Consensus  (2701) AACCTTATTATCCTGATCA GTAGTTAATCATTACTTCCAGACCCGACAT 
                                  2751                                          2800 
 HBV A1 Uganda (AY934772)  (2751) TATTTACATACTCTTTGGAAGGCTGGGATTCTATATAAGAGGGAAACTAC 
 HBV A1 Gambia (AY934764)  (2751) TATTTACATACTCTTTGGAAGGCTGGTATTCTATATAAGAGGGAAACTAC 
HBV A1 Germany (AY738139)  (2751) TATTTACATACTCTTTGGAAGGCTGGTATTCTATATAAGAGGGAAACCAC 
                Consensus  (2751) TATTTACATACTCTTTGGAAGGCTGGTATTCTATATAAGAGGGAAACTAC 
                                  2801                                          2850 
 HBV A1 Uganda (AY934772)  (2801) ACGTAGCGCCTCATTTTGCGGGTCACCATACTCTTGGGAACAAGAGCTAC 
 HBV A1 Gambia (AY934764)  (2801) ACGTAGCGCCTCATTTTGCGGGTCACCATATTCTTGGGAACAAGAGCTAC 
HBV A1 Germany (AY738139)  (2801) ACGTAGCGCATCATTTTGCGGGTCACCATATTCTTGGGAACAAGAGCTAC 
                Consensus  (2801) ACGTAGCGCCTCATTTTGCGGGTCACCATATTCTTGGGAACAAGAGCTAC 
                                  2851                                          2900 
 HBV A1 Uganda (AY934772)  (2851) ATCATGGGAGGTTGGTTACCAAAACCTCGCAAAGGCATGGGGACAAATCT 
 HBV A1 Gambia (AY934764)  (2851) ATCATGGGAGGTTGGTTACCAAAACCTCGCAAAGGCATGGGGACGAATCT 
HBV A1 Germany (AY738139)  (2851) AGCATGGGAGGTTGGTCATCAAAACCTCGCAAAGGCATGGGGACGAATCT 
                Consensus  (2851) ATCATGGGAGGTTGGTTACCAAAACCTCGCAAAGGCATGGGGACGAATCT 
                                  2901                                          2950 
 HBV A1 Uganda (AY934772)  (2901) TTCTGTTCCCAATCCTCTGGGATTCTTTCCCGATCATCAGTTGGACCCTG 
 HBV A1 Gambia (AY934764)  (2901) ATCTGTTCCCAACCCTCTGGGATTCTTTCCCGATCATCAGTTGGACCCTG 
HBV A1 Germany (AY738139)  (2901) TTCTGTTCCCAACCCTCTGGGATTCTTTCCCGATCATCAGTTGGACCCTG 
                Consensus  (2901) TTCTGTTCCCAACCCTCTGGGATTCTTTCCCGATCATCAGTTGGACCCTG 
                                  2951                                          3000 
 HBV A1 Uganda (AY934772)  (2951) CATTCGGAGCCAATTCAAACAATCCAGACTGGGACTTCAACCCCATCAAG 
 HBV A1 Gambia (AY934764)  (2951) CATTCGGAGCCAACACAAACAATCCAGATTGGGACTTCAACCCCATCAAG 
HBV A1 Germany (AY738139)  (2951) CATTCGGAGCCAACTCAAACAATCCAGATTGGGACTTCAACCCCATCAAG 
                Consensus  (2951) CATTCGGAGCCAACTCAAACAATCCAGATTGGGACTTCAACCCCATCAAG 
                                  3001                                          3050 
 HBV A1 Uganda (AY934772)  (3001) GACCACTGGCCACAAGCCAACCAGGTAGGAGTGGGAGCATTCGGCCCAGG 
 HBV A1 Gambia (AY934764)  (3001) GACCACTGGCCACAAGCCAATCAGGTAGGAGTGGGAGCATTTGGGCCAGG 
HBV A1 Germany (AY738139)  (3001) GACCACTGGCCAGCAGCCAACCAGGTAGGAGTGGGAGCATTCGGGCCAGG 
                Consensus  (3001) GACCACTGGCCACAAGCCAACCAGGTAGGAGTGGGAGCATTCGGGCCAGG 
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                                  3051                                          3100 
 HBV A1 Uganda (AY934772)  (3051) GTTCACTCCCCCACACGGAGGTGTTTTGGGGTGGAGCCCTCAGGCTCAGG 
 HBV A1 Gambia (AY934764)  (3051) GTTCACCCCTCCTCACGGAGGTGTTCTGGGGTGGAGCCCTCAGGCTCAGG 
HBV A1 Germany (AY738139)  (3051) GCTCACCCCTCCACACGGGGGTATTTTGGGGTGGAGCCCTCAGGCTCAGG 
                Consensus  (3051) GTTCACCCCTCCACACGGAGGTGTTTTGGGGTGGAGCCCTCAGGCTCAGG 
                                  3101                                          3150 
 HBV A1 Uganda (AY934772)  (3101) GCATATTGGCTACAGTGCCAGCAGTGCCTCCTCCTGCCTCCACCAATCGG 
 HBV A1 Gambia (AY934764)  (3101) GCATATCGACTACTGTGCCAGCAGTTCCTCCTCCTGCCTGCACCAATCGG 
HBV A1 Germany (AY738139)  (3101) GCATATTGACCACAGTGTCAACAATTCCTCCTCCTGCCTCCACCAATCGG 
                Consensus  (3101) GCATATTGACTACAGTGCCAGCAGTTCCTCCTCCTGCCTCCACCAATCGG 
                                  3151                                          3200 
 HBV A1 Uganda (AY934772)  (3151) CAGTCAGGAAGGCAGCCTACTCCCATCTCTCCACCTCTAAGAGACAGTCA 
 HBV A1 Gambia (AY934764)  (3151) CAGTCAGGAAGGCAGCCTACTCCCATCTCTCCACCTCTAAGAGACAGTCA 
HBV A1 Germany (AY738139)  (3151) CAGTCAGGAAGGCAGCCTACTCCCATCTCTCCACCTCTAAGAGACAGTCA 
                Consensus  (3151) CAGTCAGGAAGGCAGCCTACTCCCATCTCTCCACCTCTAAGAGACAGTCA 
                                  3201             3221 
 HBV A1 Uganda (AY934772)  (3201) TCCTCAGGCCATGCAGTGGAA 
 HBV A1 Gambia (AY934764)  (3201) TCCTCAGGCCATGCAGTGGAA 
HBV A1 Germany (AY738139)  (3201) TCCTCAGGCCATGCAGTGGAA 
                Consensus  (3201) TCCTCAGGCCATGCAGTGGAA 
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